[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$firplXqQWDQlcbSotYW7RLnF3aXVDUmR6hBkHKwU_DA4":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":85,"rows":92},"Thomas Jefferson University",[4],384,false,84,22,47126,60,222,[14,17,20,22,25,28,31,33],{"name":15,"count":16},"Migraine",14,{"name":18,"count":19},"Malignant Solid Neoplasm",8,{"name":21,"count":19},"Heart Failure",{"name":23,"count":24},"Pain",7,{"name":26,"count":27},"Breast Cancer",6,{"name":29,"count":30},"Hematopoietic and Lymphoid Cell Neoplasm",5,{"name":32,"count":30},"Depression",{"name":34,"count":30},"Preterm Birth",[36,41,46,51,56,61,66,71,76,81],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT02023463","Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer","2017-07-10","Enzalutamide",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT03489239","Entecavir to TAF Switch","2020-08-15","Tenofovir Alafenamide",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT04447716","An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab\u002FHyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment","2024-05-16","Venetoclax",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT05055323","A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer","2024-08-01","Pyrvinium Pamoate",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT04459052","FDOPA PET and Nutritional Support in Parkinson's Disease","2025-04-11","[F-18] Fluorodopa Positron Emission Tomography",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT05336786","Prostate Cancer Diagnosis by Multiparametric Ultrasound (Wholemount)","2025-05-26","Perflutren Lipid Microspheres",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT04720456","SHAPE of Portal Hypertension in Children","2025-07","SHAPE measurement using the ultrasound contrast agent Sonazoid",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT06519929","Analgesic Techniques for Rib Fractures","2025-08-31","Lidocaine bolus (1 mg\u002Fkg) and infusion starting at 1 mg\u002Fkg\u002Fh",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT04719273","Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer","2025-12-31","Extended-release Onapristone",{"nctId":82,"briefTitle":83,"date":79,"intervention":84},"NCT03854032","Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck","Nivolumab",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,135,176,198,230,248,271,289,325,361,382,419,456,533,569,595,613,631,649,672,690,752,777,804,822,844,871,889,913,931,962,980,1005,1033,1051,1069,1087,1113,1131,1157,1175,1238,1260,1304,1332,1350,1368,1386,1404,1422,1452,1470,1493,1520,1548,1566,1593,1611,1629,1659,1685,1721,1759,1786,1804,1830,1848,1866,1890,1923,1941,1959,1985,2003,2026,2051,2075,2099,2123,2141,2159,2177,2203,2221,2246,2273,2296,2322,2347,2365,2391,2409,2433,2457,2483,2501,2532,2554,2581,2607,2625,2651,2669,2694,2721,2739,2765,2809,2846,2873,2907,2940,2966,2991,3009,3027,3045,3071,3096,3121,3146,3170,3197,3215,3240,3258,3276,3300,3325,3350,3368,3394,3412,3430,3454,3481,3505,3529,3553,3577,3616,3634,3652,3670,3695,3713,3740,3764,3789,3807,3825,3847,3871,3901,3919,3937,3960,3983,4006,4035,4059,4083,4106,4130,4148,4171,4195,4216,4246,4264,4282,4337,4363,4389,4418,4453,4485,4513,4539,4564,4589,4613,4637,4661,4682,4705,4723,4747,4770,4793,4820,4838,4856,4883,4901,4924,4950,4973,4991,5014,5037,5055,5078,5096,5121,5145,5163,5181,5207,5230],{"intervention":94,"totalTrials":95,"cells":96},"ketamine",2,{"EARLY_PHASE1":97,"PHASE1":110,"PHASE2":112,"PHASE3":114,"PHASE4":116,"NA":133},{"trials":98,"activeCount":109},[99],{"nctId":100,"briefTitle":101,"status":102,"phases":103,"primaryCompletion":104,"completion":104,"start":105,"enrollment":27,"conditions":106,"interventions":108},"NCT03896256","Ketamine for Refractory Chronic Migraine: a Pilot Study","COMPLETED",[86],"2020-01-01","2019-03-22",[107],"Migraine Headache With Intractable Migraine",[94],0,{"trials":111,"activeCount":109},[],{"trials":113,"activeCount":109},[],{"trials":115,"activeCount":109},[],{"trials":117,"activeCount":132,"soonestReadout":123},[118],{"nctId":119,"briefTitle":120,"status":121,"phases":122,"primaryCompletion":123,"completion":124,"start":125,"enrollment":126,"conditions":127,"interventions":129},"NCT07177235","Ketamine for the Treatment of Refractory Status Epilepticus","NOT_YET_RECRUITING",[90],"2027-07","2028-07","2025-11",50,[128],"Refractory Status Epilepticus",[130,131],"Ketamine","Midazolam",1,{"trials":134,"activeCount":109},[],{"intervention":136,"totalTrials":95,"cells":137},"Ferumoxytol",{"EARLY_PHASE1":138,"PHASE1":140,"PHASE2":142,"PHASE3":144,"PHASE4":146,"NA":174},{"trials":139,"activeCount":109},[],{"trials":141,"activeCount":109},[],{"trials":143,"activeCount":109},[],{"trials":145,"activeCount":109},[],{"trials":147,"activeCount":132,"soonestReadout":166},[148,161],{"nctId":149,"briefTitle":150,"status":151,"phases":152,"primaryCompletion":153,"completion":153,"start":154,"enrollment":155,"conditions":156,"interventions":159},"NCT04205266","IV Iron vs Oral Iron for Treatment of Anemia in Women With Abnormal Uterine Bleeding","UNKNOWN",[90],"2025-01","2020-02-14",76,[157,158],"Anemia, Iron Deficiency","Heavy Menstrual Bleeding",[136,160],"Ferrous Sulfate",{"nctId":162,"briefTitle":163,"status":164,"phases":165,"primaryCompletion":166,"completion":167,"start":168,"enrollment":169,"conditions":170,"interventions":173},"NCT04278651","Early Antenatal Support for Iron Deficiency Anemia","RECRUITING",[90],"2026-08-30","2026-12-30","2021-09-29",80,[171,157,172],"Pregnancy Related","Anemia of Pregnancy",[136,160],{"trials":175,"activeCount":109},[],{"intervention":160,"totalTrials":95,"cells":177},{"EARLY_PHASE1":178,"PHASE1":180,"PHASE2":182,"PHASE3":184,"PHASE4":186,"NA":196},{"trials":179,"activeCount":109},[],{"trials":181,"activeCount":109},[],{"trials":183,"activeCount":109},[],{"trials":185,"activeCount":109},[],{"trials":187,"activeCount":132,"soonestReadout":166},[188,192],{"nctId":149,"briefTitle":150,"status":151,"phases":189,"primaryCompletion":153,"completion":153,"start":154,"enrollment":155,"conditions":190,"interventions":191},[90],[157,158],[136,160],{"nctId":162,"briefTitle":163,"status":164,"phases":193,"primaryCompletion":166,"completion":167,"start":168,"enrollment":169,"conditions":194,"interventions":195},[90],[171,157,172],[136,160],{"trials":197,"activeCount":109},[],{"intervention":199,"totalTrials":132,"cells":200},"Acetaminophen",{"EARLY_PHASE1":201,"PHASE1":203,"PHASE2":205,"PHASE3":207,"PHASE4":209,"NA":228},{"trials":202,"activeCount":109},[],{"trials":204,"activeCount":109},[],{"trials":206,"activeCount":109},[],{"trials":208,"activeCount":109},[],{"trials":210,"activeCount":132,"soonestReadout":215},[211],{"nctId":212,"briefTitle":213,"status":164,"phases":214,"primaryCompletion":215,"completion":216,"start":217,"enrollment":218,"conditions":219,"interventions":226},"NCT07102641","Post-cesarean Analgesia: Comparing Effectiveness of Staggered v. Simultaneous Therapies",[90],"2027-08","2027-12","2025-08-26",825,[220,221,222,223,224,225],"Cesarean Delivery","Postpartum Comfort","Postpartum Pain","Post-operative Pain","NSAIDs","Acetaminophen (D000082)",[199,227],"NSAID",{"trials":229,"activeCount":109},[],{"intervention":227,"totalTrials":132,"cells":231},{"EARLY_PHASE1":232,"PHASE1":234,"PHASE2":236,"PHASE3":238,"PHASE4":240,"NA":246},{"trials":233,"activeCount":109},[],{"trials":235,"activeCount":109},[],{"trials":237,"activeCount":109},[],{"trials":239,"activeCount":109},[],{"trials":241,"activeCount":132,"soonestReadout":215},[242],{"nctId":212,"briefTitle":213,"status":164,"phases":243,"primaryCompletion":215,"completion":216,"start":217,"enrollment":218,"conditions":244,"interventions":245},[90],[220,221,222,223,224,225],[199,227],{"trials":247,"activeCount":109},[],{"intervention":75,"totalTrials":132,"cells":249},{"EARLY_PHASE1":250,"PHASE1":252,"PHASE2":254,"PHASE3":256,"PHASE4":258,"NA":269},{"trials":251,"activeCount":109},[],{"trials":253,"activeCount":109},[],{"trials":255,"activeCount":109},[],{"trials":257,"activeCount":109},[],{"trials":259,"activeCount":132,"soonestReadout":74},[260],{"nctId":72,"briefTitle":73,"status":261,"phases":262,"primaryCompletion":74,"completion":263,"start":264,"enrollment":265,"conditions":266,"interventions":268},"ACTIVE_NOT_RECRUITING",[90],"2025-12-01","2024-09-23",24,[267],"Rib Fractures",[75],{"trials":270,"activeCount":109},[],{"intervention":131,"totalTrials":132,"cells":272},{"EARLY_PHASE1":273,"PHASE1":275,"PHASE2":277,"PHASE3":279,"PHASE4":281,"NA":287},{"trials":274,"activeCount":109},[],{"trials":276,"activeCount":109},[],{"trials":278,"activeCount":109},[],{"trials":280,"activeCount":109},[],{"trials":282,"activeCount":132,"soonestReadout":123},[283],{"nctId":119,"briefTitle":120,"status":121,"phases":284,"primaryCompletion":123,"completion":124,"start":125,"enrollment":126,"conditions":285,"interventions":286},[90],[128],[130,131],{"trials":288,"activeCount":109},[],{"intervention":290,"totalTrials":95,"cells":291},"SHAPE measurement",{"EARLY_PHASE1":292,"PHASE1":294,"PHASE2":296,"PHASE3":298,"PHASE4":312,"NA":323},{"trials":293,"activeCount":109},[],{"trials":295,"activeCount":109},[],{"trials":297,"activeCount":109},[],{"trials":299,"activeCount":132,"soonestReadout":304},[300],{"nctId":301,"briefTitle":302,"status":164,"phases":303,"primaryCompletion":304,"completion":305,"start":306,"enrollment":307,"conditions":308,"interventions":311},"NCT05470205","Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension; Renewal",[89],"2026-02-28","2026-04-30","2022-11-28",660,[309,310],"Liver Diseases","Portal Hypertension",[290,290],{"trials":313,"activeCount":109},[314],{"nctId":315,"briefTitle":316,"status":102,"phases":317,"primaryCompletion":318,"completion":318,"start":319,"enrollment":320,"conditions":321,"interventions":322},"NCT02489045","Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension",[90],"2019-03-31","2015-04-06",178,[309,310],[290],{"trials":324,"activeCount":109},[],{"intervention":326,"totalTrials":95,"cells":327},"Perflutren lipid microsphere",{"EARLY_PHASE1":328,"PHASE1":330,"PHASE2":332,"PHASE3":344,"PHASE4":357,"NA":359},{"trials":329,"activeCount":109},[],{"trials":331,"activeCount":109},[],{"trials":333,"activeCount":109},[334],{"nctId":335,"briefTitle":336,"status":102,"phases":337,"primaryCompletion":338,"completion":217,"start":339,"enrollment":340,"conditions":341,"interventions":343},"NCT06571786","SHAPE for ICP Assessment",[88],"2025-07-31","2024-12-15",19,[342],"Lumbar Puncture",[326],{"trials":345,"activeCount":132,"soonestReadout":350},[346],{"nctId":347,"briefTitle":348,"status":121,"phases":349,"primaryCompletion":350,"completion":351,"start":352,"enrollment":353,"conditions":354,"interventions":356},"NCT06024772","Multiparametric Ultrasound for the Diagnosis of Clinically Significant Prostate Cancer",[89],"2026-08-01","2027-02","2026-03-15",300,[355],"Prostate Carcinoma",[326],{"trials":358,"activeCount":109},[],{"trials":360,"activeCount":109},[],{"intervention":65,"totalTrials":132,"cells":362},{"EARLY_PHASE1":363,"PHASE1":365,"PHASE2":367,"PHASE3":369,"PHASE4":378,"NA":380},{"trials":364,"activeCount":109},[],{"trials":366,"activeCount":109},[],{"trials":368,"activeCount":109},[],{"trials":370,"activeCount":132,"soonestReadout":64},[371],{"nctId":62,"briefTitle":63,"status":261,"phases":372,"primaryCompletion":64,"completion":373,"start":374,"enrollment":375,"conditions":376,"interventions":377},[89],"2026-05-26","2022-06-15",70,[355],[65],{"trials":379,"activeCount":109},[],{"trials":381,"activeCount":109},[],{"intervention":45,"totalTrials":95,"cells":383},{"EARLY_PHASE1":384,"PHASE1":386,"PHASE2":388,"PHASE3":390,"PHASE4":400,"NA":402},{"trials":385,"activeCount":109},[],{"trials":387,"activeCount":109},[],{"trials":389,"activeCount":109},[],{"trials":391,"activeCount":132,"soonestReadout":44},[392],{"nctId":42,"briefTitle":43,"status":261,"phases":393,"primaryCompletion":44,"completion":394,"start":395,"enrollment":396,"conditions":397,"interventions":399},[89],"2020-09-16","2017-11-16",27,[398],"Hepatitis B",[45],{"trials":401,"activeCount":109},[],{"trials":403,"activeCount":109},[404],{"nctId":405,"briefTitle":406,"status":102,"phases":407,"primaryCompletion":408,"completion":408,"start":409,"enrollment":410,"conditions":411,"interventions":418},"NCT03646370","Assessing Virologic Success and Metabolic Changes in Patients Switching From a TDF to TAF Containing Antiretroviral Therapy Regimen",[],"2019-07-24","2018-07-25",110,[412,413,414,415,416,417],"HIV-1-infection","Metabolic Syndrome","Cardiovascular Diseases","Weight Gain","Renal Function Abnormal","Hyperglycemia",[45],{"intervention":420,"totalTrials":95,"cells":421},"Tebentafusp-Tebn",{"EARLY_PHASE1":422,"PHASE1":424,"PHASE2":426,"PHASE3":450,"PHASE4":452,"NA":454},{"trials":423,"activeCount":109},[],{"trials":425,"activeCount":109},[],{"trials":427,"activeCount":95,"soonestReadout":215},[428,437],{"nctId":429,"briefTitle":430,"status":164,"phases":431,"primaryCompletion":215,"completion":432,"start":433,"enrollment":340,"conditions":434,"interventions":436},"NCT06414590","Neoadjuvant Tebentafusp for Uveal Melanoma",[88],"2032-03","2025-09-05",[435],"Locally Advanced Unresectable Uveal Melanoma",[420],{"nctId":438,"briefTitle":439,"status":164,"phases":440,"primaryCompletion":441,"completion":442,"start":443,"enrollment":444,"conditions":445,"interventions":447},"NCT06626516","Tebentafusp-tebn With LDT in Metastatic UM",[87,88],"2030-10","2032-08","2025-10-15",109,[446],"Metastatic Uveal Melanoma",[420,448,449],"GM-CSF","BCNU",{"trials":451,"activeCount":109},[],{"trials":453,"activeCount":109},[],{"trials":455,"activeCount":109},[],{"intervention":457,"totalTrials":458,"cells":459},"Tacrolimus",3,{"EARLY_PHASE1":460,"PHASE1":462,"PHASE2":480,"PHASE3":512,"PHASE4":514,"NA":531},{"trials":461,"activeCount":109},[],{"trials":463,"activeCount":109},[464],{"nctId":465,"briefTitle":466,"status":102,"phases":467,"primaryCompletion":468,"completion":469,"start":470,"enrollment":471,"conditions":472,"interventions":476},"NCT03083782","Drug Interaction Study of Apixaban With Cyclosporine and Tacrolimus",[87],"2017-06-05","2017-06-30","2017-04-18",12,[473,474,475],"Venous Thromboembolism","Pharmacokinetics","Healthy",[477,478,457,479,479],"Apixaban alone","Cyclosporine","Apixaban",{"trials":481,"activeCount":132,"soonestReadout":486},[482],{"nctId":483,"briefTitle":484,"status":164,"phases":485,"primaryCompletion":486,"completion":486,"start":487,"enrollment":488,"conditions":489,"interventions":507},"NCT05031897","Two Step Haplo With Radiation Conditioning",[88],"2032-04","2021-10-25",63,[490,491,492,493,494,495,496,497,498,499,500,501,502,503,504,505,506],"Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia","Adult T-Cell Leukemia\u002FLymphoma","Aplastic Anemia","Chronic Lymphocytic Leukemia","Chronic Myeloid Leukemia, BCR-ABL1 Positive","Chronic Myelomonocytic Leukemia","Essential Thrombocythemia","Hematopoietic and Lymphatic System Neoplasm","Hodgkin Lymphoma","Multiple Myeloma","Myelodysplastic Syndrome","Myelofibrosis","Myeloid Neoplasm","Non-Hodgkin Lymphoma","Polycythemia Vera","Small Lymphocytic Lymphoma",[508,509,457,510,511],"Fludarabine","Cyclophosphamide","Mycophenolate Mofetil","Melphalan",{"trials":513,"activeCount":109},[],{"trials":515,"activeCount":109},[516],{"nctId":517,"briefTitle":518,"status":102,"phases":519,"primaryCompletion":520,"completion":521,"start":522,"enrollment":523,"conditions":524,"interventions":527},"NCT00296244","Steroid Free Immunosuppression in Liver Transplantation",[90],"2008-05","2008-06","2006-02",40,[525,526],"Liver Cirrhosis","Liver Transplant Disorder",[528,529,457,530],"Steroids","Basiliximab","Enteric-coated Mycophenolic acid",{"trials":532,"activeCount":109},[],{"intervention":509,"totalTrials":95,"cells":534},{"EARLY_PHASE1":535,"PHASE1":537,"PHASE2":539,"PHASE3":563,"PHASE4":565,"NA":567},{"trials":536,"activeCount":109},[],{"trials":538,"activeCount":109},[],{"trials":540,"activeCount":132,"soonestReadout":486},[541,545],{"nctId":483,"briefTitle":484,"status":164,"phases":542,"primaryCompletion":486,"completion":486,"start":487,"enrollment":488,"conditions":543,"interventions":544},[88],[490,491,492,493,494,495,496,497,498,499,500,501,502,503,504,505,506],[508,509,457,510,511],{"nctId":546,"briefTitle":547,"status":548,"phases":549,"primaryCompletion":550,"completion":551,"start":552,"enrollment":109,"conditions":553,"interventions":559},"NCT04418219","Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer","WITHDRAWN",[87,88],"2023-01-01","2024-01-01","2020-12-21",[554,555,556,557,558],"Anatomic Stage IV Breast Cancer AJCC v8","Metastatic Breast Carcinoma","Prognostic Stage IV Breast Cancer AJCC v8","Recurrent Breast Carcinoma","Refractory Breast Carcinoma",[509,560,561,562],"Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM","Pembrolizumab","Recombinant Interferon Alpha 2b-like Protein",{"trials":564,"activeCount":109},[],{"trials":566,"activeCount":109},[],{"trials":568,"activeCount":109},[],{"intervention":570,"totalTrials":132,"cells":571},"Ultrasound-triggered microbubble destruction with antibiotics",{"EARLY_PHASE1":572,"PHASE1":574,"PHASE2":576,"PHASE3":589,"PHASE4":591,"NA":593},{"trials":573,"activeCount":109},[],{"trials":575,"activeCount":109},[],{"trials":577,"activeCount":132,"soonestReadout":582},[578],{"nctId":579,"briefTitle":580,"status":121,"phases":581,"primaryCompletion":582,"completion":583,"start":584,"enrollment":585,"conditions":586,"interventions":588},"NCT07599865","Periprosthetic Joint Infection Bubble Study",[88],"2028-06","2030-06","2026-06",100,[587],"Periprosthetic Joint Infection (PJI)",[570],{"trials":590,"activeCount":109},[],{"trials":592,"activeCount":109},[],{"trials":594,"activeCount":109},[],{"intervention":508,"totalTrials":132,"cells":596},{"EARLY_PHASE1":597,"PHASE1":599,"PHASE2":601,"PHASE3":607,"PHASE4":609,"NA":611},{"trials":598,"activeCount":109},[],{"trials":600,"activeCount":109},[],{"trials":602,"activeCount":132,"soonestReadout":486},[603],{"nctId":483,"briefTitle":484,"status":164,"phases":604,"primaryCompletion":486,"completion":486,"start":487,"enrollment":488,"conditions":605,"interventions":606},[88],[490,491,492,493,494,495,496,497,498,499,500,501,502,503,504,505,506],[508,509,457,510,511],{"trials":608,"activeCount":109},[],{"trials":610,"activeCount":109},[],{"trials":612,"activeCount":109},[],{"intervention":510,"totalTrials":132,"cells":614},{"EARLY_PHASE1":615,"PHASE1":617,"PHASE2":619,"PHASE3":625,"PHASE4":627,"NA":629},{"trials":616,"activeCount":109},[],{"trials":618,"activeCount":109},[],{"trials":620,"activeCount":132,"soonestReadout":486},[621],{"nctId":483,"briefTitle":484,"status":164,"phases":622,"primaryCompletion":486,"completion":486,"start":487,"enrollment":488,"conditions":623,"interventions":624},[88],[490,491,492,493,494,495,496,497,498,499,500,501,502,503,504,505,506],[508,509,457,510,511],{"trials":626,"activeCount":109},[],{"trials":628,"activeCount":109},[],{"trials":630,"activeCount":109},[],{"intervention":511,"totalTrials":132,"cells":632},{"EARLY_PHASE1":633,"PHASE1":635,"PHASE2":637,"PHASE3":643,"PHASE4":645,"NA":647},{"trials":634,"activeCount":109},[],{"trials":636,"activeCount":109},[],{"trials":638,"activeCount":132,"soonestReadout":486},[639],{"nctId":483,"briefTitle":484,"status":164,"phases":640,"primaryCompletion":486,"completion":486,"start":487,"enrollment":488,"conditions":641,"interventions":642},[88],[490,491,492,493,494,495,496,497,498,499,500,501,502,503,504,505,506],[508,509,457,510,511],{"trials":644,"activeCount":109},[],{"trials":646,"activeCount":109},[],{"trials":648,"activeCount":109},[],{"intervention":70,"totalTrials":132,"cells":650},{"EARLY_PHASE1":651,"PHASE1":653,"PHASE2":655,"PHASE3":666,"PHASE4":668,"NA":670},{"trials":652,"activeCount":109},[],{"trials":654,"activeCount":109},[],{"trials":656,"activeCount":132,"soonestReadout":69},[657],{"nctId":67,"briefTitle":68,"status":164,"phases":658,"primaryCompletion":69,"completion":659,"start":660,"enrollment":661,"conditions":662,"interventions":664},[88],"2025-08","2021-11-03",120,[663],"Hypertension, Portal",[70,665],"SHAPE measurement using the ultrasound contrast agent Lumason",{"trials":667,"activeCount":109},[],{"trials":669,"activeCount":109},[],{"trials":671,"activeCount":109},[],{"intervention":665,"totalTrials":132,"cells":673},{"EARLY_PHASE1":674,"PHASE1":676,"PHASE2":678,"PHASE3":684,"PHASE4":686,"NA":688},{"trials":675,"activeCount":109},[],{"trials":677,"activeCount":109},[],{"trials":679,"activeCount":132,"soonestReadout":69},[680],{"nctId":67,"briefTitle":68,"status":164,"phases":681,"primaryCompletion":69,"completion":659,"start":660,"enrollment":661,"conditions":682,"interventions":683},[88],[663],[70,665],{"trials":685,"activeCount":109},[],{"trials":687,"activeCount":109},[],{"trials":689,"activeCount":109},[],{"intervention":691,"totalTrials":132,"cells":692},"Adenovirus 5\u002FF35-Human Guanylyl Cyclase C-PADRE",{"EARLY_PHASE1":693,"PHASE1":695,"PHASE2":697,"PHASE3":746,"PHASE4":748,"NA":750},{"trials":694,"activeCount":109},[],{"trials":696,"activeCount":109},[],{"trials":698,"activeCount":132,"soonestReadout":703},[699],{"nctId":700,"briefTitle":701,"status":261,"phases":702,"primaryCompletion":703,"completion":704,"start":705,"enrollment":706,"conditions":707,"interventions":745},"NCT04111172","A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma",[88],"2026-03-01","2027-03-01","2020-11-10",48,[708,709,710,711,712,713,714,715,716,18,717,718,719,720,721,722,723,724,725,726,727,728,729,730,731,732,733,734,735,736,737,738,739,740,741,742,743,744],"Pancreatic Ductal Adenocarcinoma","Colorectal Adenocarcinoma","Gastric Adenocarcinoma","Clinical Stage II Gastric Cancer AJCC v8","Clinical Stage IIA Gastric Cancer AJCC v8","Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8","Clinical Stage IIB Gastric Cancer AJCC v8","Clinical Stage III Esophageal Adenocarcinoma AJCC v8","Clinical Stage III Gastric Cancer AJCC v8","Pathologic Stage II Gastric Cancer AJCC v8","Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8","Pathologic Stage IIB Gastric Cancer AJCC v8","Pathologic Stage III Esophageal Adenocarcinoma AJCC v8","Pathologic Stage III Gastric Cancer AJCC v8","Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8","Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8","Pathologic Stage IIIA Gastric Cancer AJCC v8","Pathologic Stage IIIB Gastric Cancer AJCC v8","Pathologic Stage IIIC Gastric Cancer AJCC v8","Stage I Pancreatic Cancer AJCC v8","Stage IA Pancreatic Cancer AJCC v8","Stage IB Pancreatic Cancer AJCC v8","Stage II Pancreatic Cancer AJCC v8","Stage IIA Pancreatic Cancer AJCC v8","Stage IIB Pancreatic Cancer AJCC v8","Stage III Colorectal Cancer AJCC v8","Stage III Pancreatic Cancer AJCC v8","Stage IIIA Colorectal Cancer AJCC v8","Stage IIIB Colorectal Cancer AJCC v8","Stage IIIC Colorectal Cancer AJCC v8","Stage IV Colorectal Cancer AJCC v8","Stage IVA Colorectal Cancer AJCC v8","Stage IVB Colorectal Cancer AJCC v8","Malignant Digestive System Neoplasm","Small Intestinal Adenocarcinoma","Stage III Small Intestinal Adenocarcinoma AJCC v8","Stage IIIA Small Intestinal Adenocarcinoma AJCC v8",[691],{"trials":747,"activeCount":109},[],{"trials":749,"activeCount":109},[],{"trials":751,"activeCount":109},[],{"intervention":753,"totalTrials":132,"cells":754},"Perfluten",{"EARLY_PHASE1":755,"PHASE1":757,"PHASE2":759,"PHASE3":771,"PHASE4":773,"NA":775},{"trials":756,"activeCount":109},[],{"trials":758,"activeCount":109},[],{"trials":760,"activeCount":132,"soonestReadout":765},[761],{"nctId":762,"briefTitle":763,"status":164,"phases":764,"primaryCompletion":765,"completion":766,"start":767,"enrollment":169,"conditions":768,"interventions":770},"NCT06705075","Evaluation of Uterine Fibroids by CEUS and SHAPE Pre and Post UAE",[88],"2026-08-31","2026-09-30","2025-01-27",[769],"Uterine Fibroid",[753],{"trials":772,"activeCount":109},[],{"trials":774,"activeCount":109},[],{"trials":776,"activeCount":109},[],{"intervention":80,"totalTrials":132,"cells":778},{"EARLY_PHASE1":779,"PHASE1":781,"PHASE2":783,"PHASE3":798,"PHASE4":800,"NA":802},{"trials":780,"activeCount":109},[],{"trials":782,"activeCount":109},[],{"trials":784,"activeCount":132,"soonestReadout":79},[785],{"nctId":77,"briefTitle":78,"status":261,"phases":786,"primaryCompletion":79,"completion":79,"start":787,"enrollment":16,"conditions":788,"interventions":796},[88],"2021-01-28",[789,790,791,792,793,794,795],"Refractory Endometrial Adenocarcinoma","Refractory Endometrial Carcinoma","Refractory Endometrial Clear Cell Adenocarcinoma","Refractory Endometrial Endometrioid Adenocarcinoma","Refractory Endometrial Mixed Cell Adenocarcinoma","Refractory Endometrial Serous Adenocarcinoma","Refractory Endometrial Undifferentiated Carcinoma",[80,797],"Anastrozole",{"trials":799,"activeCount":109},[],{"trials":801,"activeCount":109},[],{"trials":803,"activeCount":109},[],{"intervention":797,"totalTrials":132,"cells":805},{"EARLY_PHASE1":806,"PHASE1":808,"PHASE2":810,"PHASE3":816,"PHASE4":818,"NA":820},{"trials":807,"activeCount":109},[],{"trials":809,"activeCount":109},[],{"trials":811,"activeCount":132,"soonestReadout":79},[812],{"nctId":77,"briefTitle":78,"status":261,"phases":813,"primaryCompletion":79,"completion":79,"start":787,"enrollment":16,"conditions":814,"interventions":815},[88],[789,790,791,792,793,794,795],[80,797],{"trials":817,"activeCount":109},[],{"trials":819,"activeCount":109},[],{"trials":821,"activeCount":109},[],{"intervention":60,"totalTrials":132,"cells":823},{"EARLY_PHASE1":824,"PHASE1":826,"PHASE2":828,"PHASE3":838,"PHASE4":840,"NA":842},{"trials":825,"activeCount":109},[],{"trials":827,"activeCount":109},[],{"trials":829,"activeCount":132,"soonestReadout":59},[830],{"nctId":57,"briefTitle":58,"status":261,"phases":831,"primaryCompletion":59,"completion":832,"start":833,"enrollment":126,"conditions":834,"interventions":837},[88],"2027-01-08","2020-04-30",[835,836],"Parkinson Disease","Idiopathic Parkinson Disease",[60],{"trials":839,"activeCount":109},[],{"trials":841,"activeCount":109},[],{"trials":843,"activeCount":109},[],{"intervention":845,"totalTrials":132,"cells":846},"Daily aspirin",{"EARLY_PHASE1":847,"PHASE1":849,"PHASE2":851,"PHASE3":865,"PHASE4":867,"NA":869},{"trials":848,"activeCount":109},[],{"trials":850,"activeCount":109},[],{"trials":852,"activeCount":132,"soonestReadout":857},[853],{"nctId":854,"briefTitle":855,"status":164,"phases":856,"primaryCompletion":857,"completion":858,"start":859,"enrollment":860,"conditions":861,"interventions":863},"NCT06826859","Daily Aspirin vs Split Dosing in High-risk Pregnancies (DASH)",[87,88],"2029-07-01","2029-12-31","2025-06-26",400,[34,862],"Preeclampsia",[845,864],"Split dose aspirin",{"trials":866,"activeCount":109},[],{"trials":868,"activeCount":109},[],{"trials":870,"activeCount":109},[],{"intervention":864,"totalTrials":132,"cells":872},{"EARLY_PHASE1":873,"PHASE1":875,"PHASE2":877,"PHASE3":883,"PHASE4":885,"NA":887},{"trials":874,"activeCount":109},[],{"trials":876,"activeCount":109},[],{"trials":878,"activeCount":132,"soonestReadout":857},[879],{"nctId":854,"briefTitle":855,"status":164,"phases":880,"primaryCompletion":857,"completion":858,"start":859,"enrollment":860,"conditions":881,"interventions":882},[87,88],[34,862],[845,864],{"trials":884,"activeCount":109},[],{"trials":886,"activeCount":109},[],{"trials":888,"activeCount":109},[],{"intervention":890,"totalTrials":132,"cells":891},"Plerixafor",{"EARLY_PHASE1":892,"PHASE1":894,"PHASE2":896,"PHASE3":907,"PHASE4":909,"NA":911},{"trials":893,"activeCount":109},[],{"trials":895,"activeCount":109},[],{"trials":897,"activeCount":132,"soonestReadout":216},[898],{"nctId":899,"briefTitle":900,"status":164,"phases":901,"primaryCompletion":216,"completion":582,"start":902,"enrollment":585,"conditions":903,"interventions":905},"NCT07188090","Mozobil for Autologous Hematopoietic Stem Cell Transplantation",[88],"2025-10-16",[500,499,904],"Non-hodgkin Lymphoma",[890,906],"Gcsf",{"trials":908,"activeCount":109},[],{"trials":910,"activeCount":109},[],{"trials":912,"activeCount":109},[],{"intervention":906,"totalTrials":132,"cells":914},{"EARLY_PHASE1":915,"PHASE1":917,"PHASE2":919,"PHASE3":925,"PHASE4":927,"NA":929},{"trials":916,"activeCount":109},[],{"trials":918,"activeCount":109},[],{"trials":920,"activeCount":132,"soonestReadout":216},[921],{"nctId":899,"briefTitle":900,"status":164,"phases":922,"primaryCompletion":216,"completion":582,"start":902,"enrollment":585,"conditions":923,"interventions":924},[88],[500,499,904],[890,906],{"trials":926,"activeCount":109},[],{"trials":928,"activeCount":109},[],{"trials":930,"activeCount":109},[],{"intervention":932,"totalTrials":132,"cells":933},"Pacritinib",{"EARLY_PHASE1":934,"PHASE1":936,"PHASE2":938,"PHASE3":956,"PHASE4":958,"NA":960},{"trials":935,"activeCount":109},[],{"trials":937,"activeCount":109},[],{"trials":939,"activeCount":132,"soonestReadout":944},[940],{"nctId":941,"briefTitle":942,"status":121,"phases":943,"primaryCompletion":944,"completion":944,"start":945,"enrollment":946,"conditions":947,"interventions":954},"NCT07387354","Pacritinib With Aza for Upfront Myelodysplastic Syndrome",[87,88],"2027-01","2026-05",25,[948,949,950,951,952,953],"Myelodysplastic Syndromes","MDS","Myelodysplastic Syndrome, Unclassifiable","Hematologic Diseases","Bone Marrow Disease","Myeloproliferative Neoplasm",[932,955],"Azacitidine",{"trials":957,"activeCount":109},[],{"trials":959,"activeCount":109},[],{"trials":961,"activeCount":109},[],{"intervention":955,"totalTrials":132,"cells":963},{"EARLY_PHASE1":964,"PHASE1":966,"PHASE2":968,"PHASE3":974,"PHASE4":976,"NA":978},{"trials":965,"activeCount":109},[],{"trials":967,"activeCount":109},[],{"trials":969,"activeCount":132,"soonestReadout":944},[970],{"nctId":941,"briefTitle":942,"status":121,"phases":971,"primaryCompletion":944,"completion":944,"start":945,"enrollment":946,"conditions":972,"interventions":973},[87,88],[948,949,950,951,952,953],[932,955],{"trials":975,"activeCount":109},[],{"trials":977,"activeCount":109},[],{"trials":979,"activeCount":109},[],{"intervention":981,"totalTrials":132,"cells":982},"50% Dextrose Pleurodesis",{"EARLY_PHASE1":983,"PHASE1":985,"PHASE2":987,"PHASE3":999,"PHASE4":1001,"NA":1003},{"trials":984,"activeCount":109},[],{"trials":986,"activeCount":109},[],{"trials":988,"activeCount":132,"soonestReadout":993},[989],{"nctId":990,"briefTitle":991,"status":121,"phases":992,"primaryCompletion":993,"completion":994,"start":995,"enrollment":169,"conditions":996,"interventions":998},"NCT07548047","Effectiveness of Dextrose Pleurodesis for the Management of Post-Operative Air Leak",[88],"2028-06-30","2029-06-30","2026-06-01",[997],"Post Operative Pulmonary Air Leak",[981],{"trials":1000,"activeCount":109},[],{"trials":1002,"activeCount":109},[],{"trials":1004,"activeCount":109},[],{"intervention":1006,"totalTrials":132,"cells":1007},"Carmustine",{"EARLY_PHASE1":1008,"PHASE1":1010,"PHASE2":1012,"PHASE3":1027,"PHASE4":1029,"NA":1031},{"trials":1009,"activeCount":109},[],{"trials":1011,"activeCount":109},[],{"trials":1013,"activeCount":132,"soonestReadout":1018},[1014],{"nctId":1015,"briefTitle":1016,"status":261,"phases":1017,"primaryCompletion":1018,"completion":1019,"start":1020,"enrollment":1021,"conditions":1022,"interventions":1025},"NCT04728633","Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases",[88],"2027-01-31","2027-06-30","2021-09-27",28,[1023,446,1024],"Metastatic Malignant Neoplasm in the Liver","Stage IV Choroidal and Ciliary Body Melanoma AJCC V8",[1006,1026],"Ethiodized Oil",{"trials":1028,"activeCount":109},[],{"trials":1030,"activeCount":109},[],{"trials":1032,"activeCount":109},[],{"intervention":1026,"totalTrials":132,"cells":1034},{"EARLY_PHASE1":1035,"PHASE1":1037,"PHASE2":1039,"PHASE3":1045,"PHASE4":1047,"NA":1049},{"trials":1036,"activeCount":109},[],{"trials":1038,"activeCount":109},[],{"trials":1040,"activeCount":132,"soonestReadout":1018},[1041],{"nctId":1015,"briefTitle":1016,"status":261,"phases":1042,"primaryCompletion":1018,"completion":1019,"start":1020,"enrollment":1021,"conditions":1043,"interventions":1044},[88],[1023,446,1024],[1006,1026],{"trials":1046,"activeCount":109},[],{"trials":1048,"activeCount":109},[],{"trials":1050,"activeCount":109},[],{"intervention":448,"totalTrials":132,"cells":1052},{"EARLY_PHASE1":1053,"PHASE1":1055,"PHASE2":1057,"PHASE3":1063,"PHASE4":1065,"NA":1067},{"trials":1054,"activeCount":109},[],{"trials":1056,"activeCount":109},[],{"trials":1058,"activeCount":132,"soonestReadout":441},[1059],{"nctId":438,"briefTitle":439,"status":164,"phases":1060,"primaryCompletion":441,"completion":442,"start":443,"enrollment":444,"conditions":1061,"interventions":1062},[87,88],[446],[420,448,449],{"trials":1064,"activeCount":109},[],{"trials":1066,"activeCount":109},[],{"trials":1068,"activeCount":109},[],{"intervention":449,"totalTrials":132,"cells":1070},{"EARLY_PHASE1":1071,"PHASE1":1073,"PHASE2":1075,"PHASE3":1081,"PHASE4":1083,"NA":1085},{"trials":1072,"activeCount":109},[],{"trials":1074,"activeCount":109},[],{"trials":1076,"activeCount":132,"soonestReadout":441},[1077],{"nctId":438,"briefTitle":439,"status":164,"phases":1078,"primaryCompletion":441,"completion":442,"start":443,"enrollment":444,"conditions":1079,"interventions":1080},[87,88],[446],[420,448,449],{"trials":1082,"activeCount":109},[],{"trials":1084,"activeCount":109},[],{"trials":1086,"activeCount":109},[],{"intervention":84,"totalTrials":132,"cells":1088},{"EARLY_PHASE1":1089,"PHASE1":1091,"PHASE2":1093,"PHASE3":1107,"PHASE4":1109,"NA":1111},{"trials":1090,"activeCount":109},[],{"trials":1092,"activeCount":109},[],{"trials":1094,"activeCount":132,"soonestReadout":79},[1095],{"nctId":82,"briefTitle":83,"status":261,"phases":1096,"primaryCompletion":79,"completion":79,"start":1097,"enrollment":1098,"conditions":1099,"interventions":1105},[88],"2019-04-09",45,[1100,1101,1102,1103,1104],"Lip","Oral Cavity Squamous Cell Carcinoma","Pharynx","Larynx","Squamous Cell Carcinoma",[84,1106],"IDO1 Inhibitor BMS-986205",{"trials":1108,"activeCount":109},[],{"trials":1110,"activeCount":109},[],{"trials":1112,"activeCount":109},[],{"intervention":1106,"totalTrials":132,"cells":1114},{"EARLY_PHASE1":1115,"PHASE1":1117,"PHASE2":1119,"PHASE3":1125,"PHASE4":1127,"NA":1129},{"trials":1116,"activeCount":109},[],{"trials":1118,"activeCount":109},[],{"trials":1120,"activeCount":132,"soonestReadout":79},[1121],{"nctId":82,"briefTitle":83,"status":261,"phases":1122,"primaryCompletion":79,"completion":79,"start":1097,"enrollment":1098,"conditions":1123,"interventions":1124},[88],[1100,1101,1102,1103,1104],[84,1106],{"trials":1126,"activeCount":109},[],{"trials":1128,"activeCount":109},[],{"trials":1130,"activeCount":109},[],{"intervention":1132,"totalTrials":132,"cells":1133},"Cemiplimab",{"EARLY_PHASE1":1134,"PHASE1":1136,"PHASE2":1138,"PHASE3":1151,"PHASE4":1153,"NA":1155},{"trials":1135,"activeCount":109},[],{"trials":1137,"activeCount":109},[],{"trials":1139,"activeCount":132,"soonestReadout":1144},[1140],{"nctId":1141,"briefTitle":1142,"status":164,"phases":1143,"primaryCompletion":1144,"completion":1144,"start":1145,"enrollment":375,"conditions":1146,"interventions":1149},"NCT05929664","Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery",[88],"2031-07-05","2023-07-05",[1147,1148],"Locally Advanced Basal Cell Carcinoma","Basal Cell Carcinoma",[1132,1150],"Fianlimab",{"trials":1152,"activeCount":109},[],{"trials":1154,"activeCount":109},[],{"trials":1156,"activeCount":109},[],{"intervention":1150,"totalTrials":132,"cells":1158},{"EARLY_PHASE1":1159,"PHASE1":1161,"PHASE2":1163,"PHASE3":1169,"PHASE4":1171,"NA":1173},{"trials":1160,"activeCount":109},[],{"trials":1162,"activeCount":109},[],{"trials":1164,"activeCount":132,"soonestReadout":1144},[1165],{"nctId":1141,"briefTitle":1142,"status":164,"phases":1166,"primaryCompletion":1144,"completion":1144,"start":1145,"enrollment":375,"conditions":1167,"interventions":1168},[88],[1147,1148],[1132,1150],{"trials":1170,"activeCount":109},[],{"trials":1172,"activeCount":109},[],{"trials":1174,"activeCount":109},[],{"intervention":1176,"totalTrials":1177,"cells":1178},"Definity",4,{"EARLY_PHASE1":1179,"PHASE1":1191,"PHASE2":1206,"PHASE3":1221,"PHASE4":1234,"NA":1236},{"trials":1180,"activeCount":132,"soonestReadout":1185},[1181],{"nctId":1182,"briefTitle":1183,"status":164,"phases":1184,"primaryCompletion":1185,"completion":1185,"start":1186,"enrollment":1187,"conditions":1188,"interventions":1190},"NCT07436364","Application of Contrast-enhanced Ultrasound in Monitoring Soft Tissue Sarcoma Response to Neoadjuvant Radiotherapy",[86],"2027-05","2026-03-23",10,[1189],"Soft Tissue Sarcoma",[1176],{"trials":1192,"activeCount":132,"soonestReadout":1197},[1193],{"nctId":1194,"briefTitle":1195,"status":164,"phases":1196,"primaryCompletion":1197,"completion":1198,"start":1199,"enrollment":27,"conditions":1200,"interventions":1205},"NCT07501650","Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer",[87],"2027-03","2028-03","2026-03-18",[1201,1202,1203,1204],"Head and Neck Cancer","Head and Neck Small Cell Carcinoma","Metastatic Head and Neck Cancer","Recurrent Head and Neck Cancer",[561,1176],{"trials":1207,"activeCount":109},[1208],{"nctId":1209,"briefTitle":1210,"status":102,"phases":1211,"primaryCompletion":1212,"completion":1212,"start":1213,"enrollment":1214,"conditions":1215,"interventions":1220},"NCT03243942","Noninvasive, Subharmonic Intra-Cardiac Pressure Measurement",[88],"2019-06-26","2017-06-01",56,[1216,1217,1218,1219,21],"Cardiac Catheterization","Blood Pressure","Heart Ventricles","Echocardiography",[1176],{"trials":1222,"activeCount":109},[1223],{"nctId":1224,"briefTitle":1225,"status":102,"phases":1226,"primaryCompletion":1227,"completion":1228,"start":1229,"enrollment":1230,"conditions":1231,"interventions":1233},"NCT05247541","Diagnosing Compartment Syndrome With SHAPE vs Elastography",[88,89],"2023-03-01","2023-12-01","2020-07-01",15,[1232],"Chronic Exertional Compartment Syndrome",[1176],{"trials":1235,"activeCount":109},[],{"trials":1237,"activeCount":109},[],{"intervention":561,"totalTrials":95,"cells":1239},{"EARLY_PHASE1":1240,"PHASE1":1242,"PHASE2":1248,"PHASE3":1254,"PHASE4":1256,"NA":1258},{"trials":1241,"activeCount":109},[],{"trials":1243,"activeCount":132,"soonestReadout":1197},[1244],{"nctId":1194,"briefTitle":1195,"status":164,"phases":1245,"primaryCompletion":1197,"completion":1198,"start":1199,"enrollment":27,"conditions":1246,"interventions":1247},[87],[1201,1202,1203,1204],[561,1176],{"trials":1249,"activeCount":109},[1250],{"nctId":546,"briefTitle":547,"status":548,"phases":1251,"primaryCompletion":550,"completion":551,"start":552,"enrollment":109,"conditions":1252,"interventions":1253},[87,88],[554,555,556,557,558],[509,560,561,562],{"trials":1255,"activeCount":109},[],{"trials":1257,"activeCount":109},[],{"trials":1259,"activeCount":109},[],{"intervention":50,"totalTrials":95,"cells":1261},{"EARLY_PHASE1":1262,"PHASE1":1264,"PHASE2":1296,"PHASE3":1298,"PHASE4":1300,"NA":1302},{"trials":1263,"activeCount":109},[],{"trials":1265,"activeCount":132,"soonestReadout":49},[1266,1279],{"nctId":1267,"briefTitle":1268,"status":102,"phases":1269,"primaryCompletion":1270,"completion":1271,"start":1272,"enrollment":27,"conditions":1273,"interventions":1276},"NCT05564650","Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome",[87],"2024-05-03","2026-05-08","2023-01-12",[501,1274,1275],"Recurrent Myelodysplastic Syndrome","Refractory Myelodysplastic Syndrome",[1277,50,1278],"Navitoclax","Decitabine",{"nctId":47,"briefTitle":48,"status":261,"phases":1280,"primaryCompletion":49,"completion":1281,"start":1282,"enrollment":1177,"conditions":1283,"interventions":1292},[87],"2027-04","2020-10-16",[1284,1285,1286,1287,1288,1289,1290,1291],"Recurrent B-Cell Non-Hodgkin Lymphoma","Recurrent Follicular Lymphoma","Recurrent Indolent Adult Non-Hodgkin Lymphoma","Recurrent Marginal Zone Lymphoma","Refractory B-Cell Non-Hodgkin Lymphoma","Refractory Follicular Lymphoma","Refractory Indolent Adult Non-Hodgkin Lymphoma","Refractory Marginal Zone Lymphoma",[50,1293,1294,1295],"Lenalidomide","Rituximab","Rituximab and Hyaluronidase Human",{"trials":1297,"activeCount":109},[],{"trials":1299,"activeCount":109},[],{"trials":1301,"activeCount":109},[],{"trials":1303,"activeCount":109},[],{"intervention":1305,"totalTrials":132,"cells":1306},"Tazemetostat",{"EARLY_PHASE1":1307,"PHASE1":1309,"PHASE2":1324,"PHASE3":1326,"PHASE4":1328,"NA":1330},{"trials":1308,"activeCount":109},[],{"trials":1310,"activeCount":132,"soonestReadout":1315},[1311],{"nctId":1312,"briefTitle":1313,"status":164,"phases":1314,"primaryCompletion":1315,"completion":1316,"start":1317,"enrollment":265,"conditions":1318,"interventions":1321},"NCT05627232","Tazemetostat and Palbociclib With CPX-351for R\u002FR AML",[87],"2028-01","2029-01","2023-08-28",[1319,1320],"Recurrent Acute Myeloid Leukemia","Refractory Acute Myeloid Leukemia",[1305,1322,1323],"Liposome-encapsulated Daunorubicin-Cytarabine","Palbociclib",{"trials":1325,"activeCount":109},[],{"trials":1327,"activeCount":109},[],{"trials":1329,"activeCount":109},[],{"trials":1331,"activeCount":109},[],{"intervention":1322,"totalTrials":132,"cells":1333},{"EARLY_PHASE1":1334,"PHASE1":1336,"PHASE2":1342,"PHASE3":1344,"PHASE4":1346,"NA":1348},{"trials":1335,"activeCount":109},[],{"trials":1337,"activeCount":132,"soonestReadout":1315},[1338],{"nctId":1312,"briefTitle":1313,"status":164,"phases":1339,"primaryCompletion":1315,"completion":1316,"start":1317,"enrollment":265,"conditions":1340,"interventions":1341},[87],[1319,1320],[1305,1322,1323],{"trials":1343,"activeCount":109},[],{"trials":1345,"activeCount":109},[],{"trials":1347,"activeCount":109},[],{"trials":1349,"activeCount":109},[],{"intervention":1323,"totalTrials":132,"cells":1351},{"EARLY_PHASE1":1352,"PHASE1":1354,"PHASE2":1360,"PHASE3":1362,"PHASE4":1364,"NA":1366},{"trials":1353,"activeCount":109},[],{"trials":1355,"activeCount":132,"soonestReadout":1315},[1356],{"nctId":1312,"briefTitle":1313,"status":164,"phases":1357,"primaryCompletion":1315,"completion":1316,"start":1317,"enrollment":265,"conditions":1358,"interventions":1359},[87],[1319,1320],[1305,1322,1323],{"trials":1361,"activeCount":109},[],{"trials":1363,"activeCount":109},[],{"trials":1365,"activeCount":109},[],{"trials":1367,"activeCount":109},[],{"intervention":1293,"totalTrials":132,"cells":1369},{"EARLY_PHASE1":1370,"PHASE1":1372,"PHASE2":1378,"PHASE3":1380,"PHASE4":1382,"NA":1384},{"trials":1371,"activeCount":109},[],{"trials":1373,"activeCount":132,"soonestReadout":49},[1374],{"nctId":47,"briefTitle":48,"status":261,"phases":1375,"primaryCompletion":49,"completion":1281,"start":1282,"enrollment":1177,"conditions":1376,"interventions":1377},[87],[1284,1285,1286,1287,1288,1289,1290,1291],[50,1293,1294,1295],{"trials":1379,"activeCount":109},[],{"trials":1381,"activeCount":109},[],{"trials":1383,"activeCount":109},[],{"trials":1385,"activeCount":109},[],{"intervention":1294,"totalTrials":132,"cells":1387},{"EARLY_PHASE1":1388,"PHASE1":1390,"PHASE2":1396,"PHASE3":1398,"PHASE4":1400,"NA":1402},{"trials":1389,"activeCount":109},[],{"trials":1391,"activeCount":132,"soonestReadout":49},[1392],{"nctId":47,"briefTitle":48,"status":261,"phases":1393,"primaryCompletion":49,"completion":1281,"start":1282,"enrollment":1177,"conditions":1394,"interventions":1395},[87],[1284,1285,1286,1287,1288,1289,1290,1291],[50,1293,1294,1295],{"trials":1397,"activeCount":109},[],{"trials":1399,"activeCount":109},[],{"trials":1401,"activeCount":109},[],{"trials":1403,"activeCount":109},[],{"intervention":1295,"totalTrials":132,"cells":1405},{"EARLY_PHASE1":1406,"PHASE1":1408,"PHASE2":1414,"PHASE3":1416,"PHASE4":1418,"NA":1420},{"trials":1407,"activeCount":109},[],{"trials":1409,"activeCount":132,"soonestReadout":49},[1410],{"nctId":47,"briefTitle":48,"status":261,"phases":1411,"primaryCompletion":49,"completion":1281,"start":1282,"enrollment":1177,"conditions":1412,"interventions":1413},[87],[1284,1285,1286,1287,1288,1289,1290,1291],[50,1293,1294,1295],{"trials":1415,"activeCount":109},[],{"trials":1417,"activeCount":109},[],{"trials":1419,"activeCount":109},[],{"trials":1421,"activeCount":109},[],{"intervention":1423,"totalTrials":132,"cells":1424},"Rivaroxaban 10 MG Oral",{"EARLY_PHASE1":1425,"PHASE1":1427,"PHASE2":1444,"PHASE3":1446,"PHASE4":1448,"NA":1450},{"trials":1426,"activeCount":109},[],{"trials":1428,"activeCount":132,"soonestReadout":1433},[1429],{"nctId":1430,"briefTitle":1431,"status":164,"phases":1432,"primaryCompletion":1433,"completion":1434,"start":69,"enrollment":1187,"conditions":1435,"interventions":1442},"NCT06831474","Excretion of Rivaroxaban in Human Breast Milk",[87],"2026-04-01","2026-07-31",[1436,1437,1438,1439,1440,1441],"Postpartum","VTE Prophylaxis","VTE (Venous Thromboembolism)","Rivaroxaban","Breastfeeding","Breast Milk Collection",[1423,1443],"Rivaroxaban 20 MG Oral",{"trials":1445,"activeCount":109},[],{"trials":1447,"activeCount":109},[],{"trials":1449,"activeCount":109},[],{"trials":1451,"activeCount":109},[],{"intervention":1443,"totalTrials":132,"cells":1453},{"EARLY_PHASE1":1454,"PHASE1":1456,"PHASE2":1462,"PHASE3":1464,"PHASE4":1466,"NA":1468},{"trials":1455,"activeCount":109},[],{"trials":1457,"activeCount":132,"soonestReadout":1433},[1458],{"nctId":1430,"briefTitle":1431,"status":164,"phases":1459,"primaryCompletion":1433,"completion":1434,"start":69,"enrollment":1187,"conditions":1460,"interventions":1461},[87],[1436,1437,1438,1439,1440,1441],[1423,1443],{"trials":1463,"activeCount":109},[],{"trials":1465,"activeCount":109},[],{"trials":1467,"activeCount":109},[],{"trials":1469,"activeCount":109},[],{"intervention":55,"totalTrials":132,"cells":1471},{"EARLY_PHASE1":1472,"PHASE1":1474,"PHASE2":1485,"PHASE3":1487,"PHASE4":1489,"NA":1491},{"trials":1473,"activeCount":109},[],{"trials":1475,"activeCount":132,"soonestReadout":54},[1476],{"nctId":52,"briefTitle":53,"status":261,"phases":1477,"primaryCompletion":54,"completion":1478,"start":1479,"enrollment":1480,"conditions":1481,"interventions":1484},[87],"2026-12-31","2021-07-29",20,[1482,1483,727,728,729,730,731,732],"Resectable Pancreatic Ductal Adenocarcinoma","Stage 0 Pancreatic Cancer AJCC v8",[55],{"trials":1486,"activeCount":109},[],{"trials":1488,"activeCount":109},[],{"trials":1490,"activeCount":109},[],{"trials":1492,"activeCount":109},[],{"intervention":1494,"totalTrials":132,"cells":1495},"VK-2019",{"EARLY_PHASE1":1496,"PHASE1":1498,"PHASE2":1512,"PHASE3":1514,"PHASE4":1516,"NA":1518},{"trials":1497,"activeCount":109},[],{"trials":1499,"activeCount":132,"soonestReadout":1504},[1500],{"nctId":1501,"briefTitle":1502,"status":164,"phases":1503,"primaryCompletion":1504,"completion":1504,"start":1505,"enrollment":1506,"conditions":1507,"interventions":1511},"NCT06789159","A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)",[87],"2028-10-01","2025-05-22",30,[1508,1509,1510],"Diffuse Large B Cell Lymphoma Refractory","Diffuse Large B Cell Lymphoma Relapsed","Epstein-Barr Virus (EBV) Infection",[1494],{"trials":1513,"activeCount":109},[],{"trials":1515,"activeCount":109},[],{"trials":1517,"activeCount":109},[],{"trials":1519,"activeCount":109},[],{"intervention":1521,"totalTrials":132,"cells":1522},"Ad5.F35-hGUCY2C-PADRE vaccine",{"EARLY_PHASE1":1523,"PHASE1":1525,"PHASE2":1540,"PHASE3":1542,"PHASE4":1544,"NA":1546},{"trials":1524,"activeCount":109},[],{"trials":1526,"activeCount":132,"soonestReadout":1531},[1527],{"nctId":1528,"briefTitle":1529,"status":164,"phases":1530,"primaryCompletion":1531,"completion":1532,"start":1533,"enrollment":1534,"conditions":1535,"interventions":1538},"NCT07417488","GUCY2C Prime-Boost Vaccination for Advanced Colorectal and Small Bowel Adenocarcinomas",[87],"2027-10","2028-04","2026-04-21",18,[1536,1537],"Colorectal Cancer","Small Bowel Adenocarcinoma",[1521,1539],"Lm-GUCY2C vaccine",{"trials":1541,"activeCount":109},[],{"trials":1543,"activeCount":109},[],{"trials":1545,"activeCount":109},[],{"trials":1547,"activeCount":109},[],{"intervention":1539,"totalTrials":132,"cells":1549},{"EARLY_PHASE1":1550,"PHASE1":1552,"PHASE2":1558,"PHASE3":1560,"PHASE4":1562,"NA":1564},{"trials":1551,"activeCount":109},[],{"trials":1553,"activeCount":132,"soonestReadout":1531},[1554],{"nctId":1528,"briefTitle":1529,"status":164,"phases":1555,"primaryCompletion":1531,"completion":1532,"start":1533,"enrollment":1534,"conditions":1556,"interventions":1557},[87],[1536,1537],[1521,1539],{"trials":1559,"activeCount":109},[],{"trials":1561,"activeCount":109},[],{"trials":1563,"activeCount":109},[],{"trials":1565,"activeCount":109},[],{"intervention":40,"totalTrials":132,"cells":1567},{"EARLY_PHASE1":1568,"PHASE1":1570,"PHASE2":1585,"PHASE3":1587,"PHASE4":1589,"NA":1591},{"trials":1569,"activeCount":109},[],{"trials":1571,"activeCount":132,"soonestReadout":39},[1572],{"nctId":37,"briefTitle":38,"status":261,"phases":1573,"primaryCompletion":39,"completion":1574,"start":1575,"enrollment":946,"conditions":1576,"interventions":1582},[87],"2040-01-01","2014-04-02",[1577,1578,1579,1580,1581],"Adenocarcinoma of the Prostate","Recurrent Prostate Cancer","Stage IIB Prostate Cancer","Stage III Prostate Cancer","Stage IV Prostate Cancer",[40,1583,1584],"Goserelin acetate","Leuprolide acetate",{"trials":1586,"activeCount":109},[],{"trials":1588,"activeCount":109},[],{"trials":1590,"activeCount":109},[],{"trials":1592,"activeCount":109},[],{"intervention":1583,"totalTrials":132,"cells":1594},{"EARLY_PHASE1":1595,"PHASE1":1597,"PHASE2":1603,"PHASE3":1605,"PHASE4":1607,"NA":1609},{"trials":1596,"activeCount":109},[],{"trials":1598,"activeCount":132,"soonestReadout":39},[1599],{"nctId":37,"briefTitle":38,"status":261,"phases":1600,"primaryCompletion":39,"completion":1574,"start":1575,"enrollment":946,"conditions":1601,"interventions":1602},[87],[1577,1578,1579,1580,1581],[40,1583,1584],{"trials":1604,"activeCount":109},[],{"trials":1606,"activeCount":109},[],{"trials":1608,"activeCount":109},[],{"trials":1610,"activeCount":109},[],{"intervention":1584,"totalTrials":132,"cells":1612},{"EARLY_PHASE1":1613,"PHASE1":1615,"PHASE2":1621,"PHASE3":1623,"PHASE4":1625,"NA":1627},{"trials":1614,"activeCount":109},[],{"trials":1616,"activeCount":132,"soonestReadout":39},[1617],{"nctId":37,"briefTitle":38,"status":261,"phases":1618,"primaryCompletion":39,"completion":1574,"start":1575,"enrollment":946,"conditions":1619,"interventions":1620},[87],[1577,1578,1579,1580,1581],[40,1583,1584],{"trials":1622,"activeCount":109},[],{"trials":1624,"activeCount":109},[],{"trials":1626,"activeCount":109},[],{"trials":1628,"activeCount":109},[],{"intervention":1630,"totalTrials":95,"cells":1631},"Insulin",{"EARLY_PHASE1":1632,"PHASE1":1634,"PHASE2":1636,"PHASE3":1638,"PHASE4":1640,"NA":1642},{"trials":1633,"activeCount":109},[],{"trials":1635,"activeCount":109},[],{"trials":1637,"activeCount":109},[],{"trials":1639,"activeCount":109},[],{"trials":1641,"activeCount":109},[],{"trials":1643,"activeCount":95,"soonestReadout":945},[1644,1653],{"nctId":1645,"briefTitle":1646,"status":164,"phases":1647,"primaryCompletion":945,"completion":945,"start":1648,"enrollment":1649,"conditions":1650,"interventions":1652},"NCT06419803","Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (START 2)",[91],"2024-09-01",430,[1651,171],"Gestational Diabetes",[1630],{"nctId":1654,"briefTitle":1655,"status":164,"phases":1656,"primaryCompletion":945,"completion":945,"start":1648,"enrollment":1649,"conditions":1657,"interventions":1658},"NCT06419777","Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes",[91],[1651,171],[1630],{"intervention":1660,"totalTrials":132,"cells":1661},"Vaginal Suppository Progesterone",{"EARLY_PHASE1":1662,"PHASE1":1664,"PHASE2":1666,"PHASE3":1668,"PHASE4":1670,"NA":1672},{"trials":1663,"activeCount":109},[],{"trials":1665,"activeCount":109},[],{"trials":1667,"activeCount":109},[],{"trials":1669,"activeCount":109},[],{"trials":1671,"activeCount":109},[],{"trials":1673,"activeCount":132,"soonestReadout":1678},[1674],{"nctId":1675,"briefTitle":1676,"status":164,"phases":1677,"primaryCompletion":1678,"completion":1679,"start":1680,"enrollment":1681,"conditions":1682,"interventions":1684},"NCT06036446","LATe Cerclage in High-risk Pregnancies (LATCH)",[91],"2028-10","2029-02","2023-11-10",329,[1683],"Premature Birth",[1660],{"intervention":1686,"totalTrials":95,"cells":1687},"Vaginal Progesterone",{"EARLY_PHASE1":1688,"PHASE1":1690,"PHASE2":1692,"PHASE3":1694,"PHASE4":1696,"NA":1719},{"trials":1689,"activeCount":109},[],{"trials":1691,"activeCount":109},[],{"trials":1693,"activeCount":109},[],{"trials":1695,"activeCount":109},[],{"trials":1697,"activeCount":109},[1698,1709],{"nctId":1699,"briefTitle":1700,"status":102,"phases":1701,"primaryCompletion":1702,"completion":1703,"start":1704,"enrollment":1705,"conditions":1706,"interventions":1707},"NCT02913495","Vaginal Versus Intramuscular Progesterone for the Prevention of Recurrent Preterm Birth",[90],"2021-08","2021-09","2016-09",210,[1683],[1686,1708],"Intramuscular Progesterone",{"nctId":1710,"briefTitle":1711,"status":102,"phases":1712,"primaryCompletion":1713,"completion":1713,"start":1714,"enrollment":1715,"conditions":1716,"interventions":1717},"NCT03251729","Cerclage On LOw Risk Singletons: Cervical Cerclage for Prevention of Spontaneous Preterm Birth in Low Risk Singleton Pregnancies With Short Cervix",[90],"2024-02-20","2017-09-22",93,[1683],[1718],"Vaginal progesterone",{"trials":1720,"activeCount":109},[],{"intervention":1722,"totalTrials":95,"cells":1723},"Oxycodone",{"EARLY_PHASE1":1724,"PHASE1":1726,"PHASE2":1728,"PHASE3":1730,"PHASE4":1732,"NA":1757},{"trials":1725,"activeCount":109},[],{"trials":1727,"activeCount":109},[],{"trials":1729,"activeCount":109},[],{"trials":1731,"activeCount":109},[],{"trials":1733,"activeCount":109},[1734,1746],{"nctId":1735,"briefTitle":1736,"status":1737,"phases":1738,"primaryCompletion":1739,"completion":1739,"start":1740,"enrollment":1741,"conditions":1742,"interventions":1745},"NCT05363436","Opioid Reduction Toolkit Reduces Opioids Prescribed and Consumed","SUSPENDED",[90],"2028-12","2018-01-01",159,[1743,1744,23],"Opioid Abuse","Opioid Misuse",[1722],{"nctId":1747,"briefTitle":1748,"status":102,"phases":1749,"primaryCompletion":1750,"completion":1751,"start":1752,"enrollment":1753,"conditions":1754,"interventions":1756},"NCT05327777","Toward Zero Prescribed Opioids for Outpatient General Surgery",[90],"2021-07-30","2023-03-15","2019-11-01",129,[1755,23],"Opioid Misuse and Addiction",[1722],{"trials":1758,"activeCount":109},[],{"intervention":1760,"totalTrials":132,"cells":1761},"Vilazodone",{"EARLY_PHASE1":1762,"PHASE1":1764,"PHASE2":1766,"PHASE3":1768,"PHASE4":1770,"NA":1784},{"trials":1763,"activeCount":109},[],{"trials":1765,"activeCount":109},[],{"trials":1767,"activeCount":109},[],{"trials":1769,"activeCount":109},[],{"trials":1771,"activeCount":109},[1772],{"nctId":1773,"briefTitle":1774,"status":1775,"phases":1776,"primaryCompletion":1777,"completion":1777,"start":1778,"enrollment":1177,"conditions":1779,"interventions":1782},"NCT01856127","Does Vilazodone Help With Antidepressant-associated Sexual Dysfunction?","TERMINATED",[90],"2016-06","2013-01",[1780,1781],"Sexual Dysfunction","Major Depressive Disorder",[1760,1783],"Sertraline",{"trials":1785,"activeCount":109},[],{"intervention":1783,"totalTrials":132,"cells":1787},{"EARLY_PHASE1":1788,"PHASE1":1790,"PHASE2":1792,"PHASE3":1794,"PHASE4":1796,"NA":1802},{"trials":1789,"activeCount":109},[],{"trials":1791,"activeCount":109},[],{"trials":1793,"activeCount":109},[],{"trials":1795,"activeCount":109},[],{"trials":1797,"activeCount":109},[1798],{"nctId":1773,"briefTitle":1774,"status":1775,"phases":1799,"primaryCompletion":1777,"completion":1777,"start":1778,"enrollment":1177,"conditions":1800,"interventions":1801},[90],[1780,1781],[1760,1783],{"trials":1803,"activeCount":109},[],{"intervention":1805,"totalTrials":132,"cells":1806},"isobaric bupivacaine",{"EARLY_PHASE1":1807,"PHASE1":1809,"PHASE2":1811,"PHASE3":1813,"PHASE4":1815,"NA":1828},{"trials":1808,"activeCount":109},[],{"trials":1810,"activeCount":109},[],{"trials":1812,"activeCount":109},[],{"trials":1814,"activeCount":109},[],{"trials":1816,"activeCount":109},[1817],{"nctId":1818,"briefTitle":1819,"status":102,"phases":1820,"primaryCompletion":1821,"completion":1821,"start":1822,"enrollment":1741,"conditions":1823,"interventions":1825},"NCT03948386","3 Local Anesthetics for Spinal Anesthesia in Primary Total Hip Arthroplasty",[90],"2019-11-11","2019-05-13",[1824],"Osteoarthritis, Hip",[1805,1826,1827],"hyperbaric bupivacaine","isobaric mepivacaine",{"trials":1829,"activeCount":109},[],{"intervention":1826,"totalTrials":132,"cells":1831},{"EARLY_PHASE1":1832,"PHASE1":1834,"PHASE2":1836,"PHASE3":1838,"PHASE4":1840,"NA":1846},{"trials":1833,"activeCount":109},[],{"trials":1835,"activeCount":109},[],{"trials":1837,"activeCount":109},[],{"trials":1839,"activeCount":109},[],{"trials":1841,"activeCount":109},[1842],{"nctId":1818,"briefTitle":1819,"status":102,"phases":1843,"primaryCompletion":1821,"completion":1821,"start":1822,"enrollment":1741,"conditions":1844,"interventions":1845},[90],[1824],[1805,1826,1827],{"trials":1847,"activeCount":109},[],{"intervention":1827,"totalTrials":132,"cells":1849},{"EARLY_PHASE1":1850,"PHASE1":1852,"PHASE2":1854,"PHASE3":1856,"PHASE4":1858,"NA":1864},{"trials":1851,"activeCount":109},[],{"trials":1853,"activeCount":109},[],{"trials":1855,"activeCount":109},[],{"trials":1857,"activeCount":109},[],{"trials":1859,"activeCount":109},[1860],{"nctId":1818,"briefTitle":1819,"status":102,"phases":1861,"primaryCompletion":1821,"completion":1821,"start":1822,"enrollment":1741,"conditions":1862,"interventions":1863},[90],[1824],[1805,1826,1827],{"trials":1865,"activeCount":109},[],{"intervention":1867,"totalTrials":132,"cells":1868},"0.375% ROPIVACAINE",{"EARLY_PHASE1":1869,"PHASE1":1871,"PHASE2":1873,"PHASE3":1875,"PHASE4":1877,"NA":1888},{"trials":1870,"activeCount":109},[],{"trials":1872,"activeCount":109},[],{"trials":1874,"activeCount":109},[],{"trials":1876,"activeCount":109},[],{"trials":1878,"activeCount":109},[1879],{"nctId":1880,"briefTitle":1881,"status":548,"phases":1882,"primaryCompletion":1883,"completion":1883,"start":1884,"enrollment":109,"conditions":1885,"interventions":1887},"NCT01644864","Can Post-operative TAP Block Improve Quality of Recovery After C-sections in Patients on Methadone Maintenance?",[90],"2013-11","2012-07",[1886],"Uncontrolled Postoperative Pain",[1867],{"trials":1889,"activeCount":109},[],{"intervention":1891,"totalTrials":132,"cells":1892},"Azithromycin 1 gram IV",{"EARLY_PHASE1":1893,"PHASE1":1895,"PHASE2":1897,"PHASE3":1899,"PHASE4":1901,"NA":1921},{"trials":1894,"activeCount":109},[],{"trials":1896,"activeCount":109},[],{"trials":1898,"activeCount":109},[],{"trials":1900,"activeCount":109},[],{"trials":1902,"activeCount":109},[1903],{"nctId":1904,"briefTitle":1905,"status":151,"phases":1906,"primaryCompletion":1907,"completion":1908,"start":1909,"enrollment":126,"conditions":1910,"interventions":1919},"NCT05132829","Azithromycin to Improve Latency in Exam Indicated Cerclage Control Trial",[90],"2024-12","2025-06","2021-12-20",[34,1911,1912,1913,1914,1915,1916,1917,1918],"Obstetric Labor, Premature","Obstetric Labor Complications","Pregnancy Complications","Physiological Effects of Drugs","Uterine Cervical Incompetence","Anti-Bacterial Agents","Azithromycin","Cefazolin",[1891,1920],"Cefazolin and indomethacin",{"trials":1922,"activeCount":109},[],{"intervention":1920,"totalTrials":132,"cells":1924},{"EARLY_PHASE1":1925,"PHASE1":1927,"PHASE2":1929,"PHASE3":1931,"PHASE4":1933,"NA":1939},{"trials":1926,"activeCount":109},[],{"trials":1928,"activeCount":109},[],{"trials":1930,"activeCount":109},[],{"trials":1932,"activeCount":109},[],{"trials":1934,"activeCount":109},[1935],{"nctId":1904,"briefTitle":1905,"status":151,"phases":1936,"primaryCompletion":1907,"completion":1908,"start":1909,"enrollment":126,"conditions":1937,"interventions":1938},[90],[34,1911,1912,1913,1914,1915,1916,1917,1918],[1891,1920],{"trials":1940,"activeCount":109},[],{"intervention":1708,"totalTrials":132,"cells":1942},{"EARLY_PHASE1":1943,"PHASE1":1945,"PHASE2":1947,"PHASE3":1949,"PHASE4":1951,"NA":1957},{"trials":1944,"activeCount":109},[],{"trials":1946,"activeCount":109},[],{"trials":1948,"activeCount":109},[],{"trials":1950,"activeCount":109},[],{"trials":1952,"activeCount":109},[1953],{"nctId":1699,"briefTitle":1700,"status":102,"phases":1954,"primaryCompletion":1702,"completion":1703,"start":1704,"enrollment":1705,"conditions":1955,"interventions":1956},[90],[1683],[1686,1708],{"trials":1958,"activeCount":109},[],{"intervention":1960,"totalTrials":132,"cells":1961},"Ropivicaine",{"EARLY_PHASE1":1962,"PHASE1":1964,"PHASE2":1966,"PHASE3":1968,"PHASE4":1970,"NA":1983},{"trials":1963,"activeCount":109},[],{"trials":1965,"activeCount":109},[],{"trials":1967,"activeCount":109},[],{"trials":1969,"activeCount":109},[],{"trials":1971,"activeCount":109},[1972],{"nctId":1973,"briefTitle":1974,"status":151,"phases":1975,"primaryCompletion":1976,"completion":1976,"start":1977,"enrollment":410,"conditions":1978,"interventions":1981},"NCT02497911","A Trial Comparing Adductor Canal Catheter and Intraarticular Catheter Following Primary Total Knee Arthroplasty",[90],"2015-11","2014-01",[1979,1980],"Acute Pain","Regional Anesthesia Morbidity",[1960,1982],"Bupivicaine",{"trials":1984,"activeCount":109},[],{"intervention":1982,"totalTrials":132,"cells":1986},{"EARLY_PHASE1":1987,"PHASE1":1989,"PHASE2":1991,"PHASE3":1993,"PHASE4":1995,"NA":2001},{"trials":1988,"activeCount":109},[],{"trials":1990,"activeCount":109},[],{"trials":1992,"activeCount":109},[],{"trials":1994,"activeCount":109},[],{"trials":1996,"activeCount":109},[1997],{"nctId":1973,"briefTitle":1974,"status":151,"phases":1998,"primaryCompletion":1976,"completion":1976,"start":1977,"enrollment":410,"conditions":1999,"interventions":2000},[90],[1979,1980],[1960,1982],{"trials":2002,"activeCount":109},[],{"intervention":2004,"totalTrials":132,"cells":2005},"bupropion extended release",{"EARLY_PHASE1":2006,"PHASE1":2008,"PHASE2":2010,"PHASE3":2012,"PHASE4":2014,"NA":2024},{"trials":2007,"activeCount":109},[],{"trials":2009,"activeCount":109},[],{"trials":2011,"activeCount":109},[],{"trials":2013,"activeCount":109},[],{"trials":2015,"activeCount":109},[2016],{"nctId":2017,"briefTitle":2018,"status":102,"phases":2019,"completion":2020,"start":2021,"enrollment":946,"conditions":2022,"interventions":2023},"NCT00234195","Wellbutrin XL, Major Depressive Disorder and Breast Cancer",[90],"2007-01","2005-09",[26,1781],[2004],{"trials":2025,"activeCount":109},[],{"intervention":2027,"totalTrials":132,"cells":2028},"bupivacaine",{"EARLY_PHASE1":2029,"PHASE1":2031,"PHASE2":2033,"PHASE3":2035,"PHASE4":2037,"NA":2049},{"trials":2030,"activeCount":109},[],{"trials":2032,"activeCount":109},[],{"trials":2034,"activeCount":109},[],{"trials":2036,"activeCount":109},[],{"trials":2038,"activeCount":109},[2039],{"nctId":2040,"briefTitle":2041,"status":548,"phases":2042,"primaryCompletion":2043,"completion":2044,"start":2045,"enrollment":109,"conditions":2046,"interventions":2047},"NCT02603900","Adductor Canal Catheter vs Local Infiltration of Analgesia for Total Knee Arthroplasty",[90],"2016-10","2016-12","2015-10",[1979,1980],[2048,2027],"ropivacaine",{"trials":2050,"activeCount":109},[],{"intervention":2052,"totalTrials":132,"cells":2053},"intrathecal hydromorphone",{"EARLY_PHASE1":2054,"PHASE1":2056,"PHASE2":2058,"PHASE3":2060,"PHASE4":2062,"NA":2073},{"trials":2055,"activeCount":109},[],{"trials":2057,"activeCount":109},[],{"trials":2059,"activeCount":109},[],{"trials":2061,"activeCount":109},[],{"trials":2063,"activeCount":109},[2064],{"nctId":2065,"briefTitle":2066,"status":102,"phases":2067,"primaryCompletion":2068,"completion":2069,"start":1977,"enrollment":2070,"conditions":2071,"interventions":2072},"NCT02067520","Intrathecal Hydromorphone for Cesarean Section",[90],"2014-12","2015-06",54,[23],[2052],{"trials":2074,"activeCount":109},[],{"intervention":2076,"totalTrials":132,"cells":2077},"methylene blue",{"EARLY_PHASE1":2078,"PHASE1":2080,"PHASE2":2082,"PHASE3":2084,"PHASE4":2086,"NA":2097},{"trials":2079,"activeCount":109},[],{"trials":2081,"activeCount":109},[],{"trials":2083,"activeCount":109},[],{"trials":2085,"activeCount":109},[],{"trials":2087,"activeCount":109},[2088],{"nctId":2089,"briefTitle":2090,"status":1775,"phases":2091,"primaryCompletion":2092,"completion":2092,"start":2093,"enrollment":126,"conditions":2094,"interventions":2096},"NCT01386879","Evaluation of Above the Cuff Suctioning During General Anesthesia",[90],"2012-10","2011-07",[2095],"Secretion Removal Above ETT Cuff",[2076],{"trials":2098,"activeCount":109},[],{"intervention":2100,"totalTrials":132,"cells":2101},"Topiramate",{"EARLY_PHASE1":2102,"PHASE1":2104,"PHASE2":2106,"PHASE3":2108,"PHASE4":2110,"NA":2121},{"trials":2103,"activeCount":109},[],{"trials":2105,"activeCount":109},[],{"trials":2107,"activeCount":109},[],{"trials":2109,"activeCount":109},[],{"trials":2111,"activeCount":109},[2112],{"nctId":2113,"briefTitle":2114,"status":1775,"phases":2115,"completion":2116,"start":2117,"enrollment":11,"conditions":2118,"interventions":2120},"NCT00203190","A Double-Blind, Placebo-Controlled Study Examining the Use of Topiramate in the Treatment of Cluster Headache",[90],"2006-06","2004-09",[2119],"Cluster Headache",[2100],{"trials":2122,"activeCount":109},[],{"intervention":528,"totalTrials":132,"cells":2124},{"EARLY_PHASE1":2125,"PHASE1":2127,"PHASE2":2129,"PHASE3":2131,"PHASE4":2133,"NA":2139},{"trials":2126,"activeCount":109},[],{"trials":2128,"activeCount":109},[],{"trials":2130,"activeCount":109},[],{"trials":2132,"activeCount":109},[],{"trials":2134,"activeCount":109},[2135],{"nctId":517,"briefTitle":518,"status":102,"phases":2136,"primaryCompletion":520,"completion":521,"start":522,"enrollment":523,"conditions":2137,"interventions":2138},[90],[525,526],[528,529,457,530],{"trials":2140,"activeCount":109},[],{"intervention":529,"totalTrials":132,"cells":2142},{"EARLY_PHASE1":2143,"PHASE1":2145,"PHASE2":2147,"PHASE3":2149,"PHASE4":2151,"NA":2157},{"trials":2144,"activeCount":109},[],{"trials":2146,"activeCount":109},[],{"trials":2148,"activeCount":109},[],{"trials":2150,"activeCount":109},[],{"trials":2152,"activeCount":109},[2153],{"nctId":517,"briefTitle":518,"status":102,"phases":2154,"primaryCompletion":520,"completion":521,"start":522,"enrollment":523,"conditions":2155,"interventions":2156},[90],[525,526],[528,529,457,530],{"trials":2158,"activeCount":109},[],{"intervention":530,"totalTrials":132,"cells":2160},{"EARLY_PHASE1":2161,"PHASE1":2163,"PHASE2":2165,"PHASE3":2167,"PHASE4":2169,"NA":2175},{"trials":2162,"activeCount":109},[],{"trials":2164,"activeCount":109},[],{"trials":2166,"activeCount":109},[],{"trials":2168,"activeCount":109},[],{"trials":2170,"activeCount":109},[2171],{"nctId":517,"briefTitle":518,"status":102,"phases":2172,"primaryCompletion":520,"completion":521,"start":522,"enrollment":523,"conditions":2173,"interventions":2174},[90],[525,526],[528,529,457,530],{"trials":2176,"activeCount":109},[],{"intervention":2178,"totalTrials":132,"cells":2179},"Migranal nasal spray at 1 hour",{"EARLY_PHASE1":2180,"PHASE1":2182,"PHASE2":2184,"PHASE3":2186,"PHASE4":2188,"NA":2201},{"trials":2181,"activeCount":109},[],{"trials":2183,"activeCount":109},[],{"trials":2185,"activeCount":109},[],{"trials":2187,"activeCount":109},[],{"trials":2189,"activeCount":109},[2190],{"nctId":2191,"briefTitle":2192,"status":102,"phases":2193,"primaryCompletion":2194,"completion":2195,"start":2196,"enrollment":2197,"conditions":2198,"interventions":2199},"NCT00335777","A Research Study Examining Migranal and Skin Sensitivity in Subjects With Migraine",[90],"2008-12","2009-04","2006-08",64,[15],[2178,2200],"Migranal nasal spray at 4 hour",{"trials":2202,"activeCount":109},[],{"intervention":2200,"totalTrials":132,"cells":2204},{"EARLY_PHASE1":2205,"PHASE1":2207,"PHASE2":2209,"PHASE3":2211,"PHASE4":2213,"NA":2219},{"trials":2206,"activeCount":109},[],{"trials":2208,"activeCount":109},[],{"trials":2210,"activeCount":109},[],{"trials":2212,"activeCount":109},[],{"trials":2214,"activeCount":109},[2215],{"nctId":2191,"briefTitle":2192,"status":102,"phases":2216,"primaryCompletion":2194,"completion":2195,"start":2196,"enrollment":2197,"conditions":2217,"interventions":2218},[90],[15],[2178,2200],{"trials":2220,"activeCount":109},[],{"intervention":2222,"totalTrials":132,"cells":2223},"Adefovir Dipivoxil",{"EARLY_PHASE1":2224,"PHASE1":2226,"PHASE2":2228,"PHASE3":2230,"PHASE4":2232,"NA":2244},{"trials":2225,"activeCount":109},[],{"trials":2227,"activeCount":109},[],{"trials":2229,"activeCount":109},[],{"trials":2231,"activeCount":109},[],{"trials":2233,"activeCount":109},[2234],{"nctId":2235,"briefTitle":2236,"status":102,"phases":2237,"primaryCompletion":2238,"completion":2239,"start":2240,"enrollment":523,"conditions":2241,"interventions":2243},"NCT00307242","Study Comparing the Safety of Switching From Lamivudine to Adefovir Dipivoxil Versus Overlapping Lamivudine and Adefovir Before Adefovir Dipivoxil Monotherapy in Patients With Chronic Hepatitis B",[90],"2009-02","2009-02-05","2005-06-17",[2242],"Chronic Hepatitis B",[2222],{"trials":2245,"activeCount":109},[],{"intervention":2247,"totalTrials":132,"cells":2248},"esomeprazole",{"EARLY_PHASE1":2249,"PHASE1":2251,"PHASE2":2253,"PHASE3":2255,"PHASE4":2257,"NA":2271},{"trials":2250,"activeCount":109},[],{"trials":2252,"activeCount":109},[],{"trials":2254,"activeCount":109},[],{"trials":2256,"activeCount":109},[],{"trials":2258,"activeCount":109},[2259],{"nctId":2260,"briefTitle":2261,"status":102,"phases":2262,"primaryCompletion":2263,"completion":2263,"start":2264,"enrollment":2265,"conditions":2266,"interventions":2270},"NCT00225238","The Effects of Nexium on the Side Effects Associated With a Colonoscopy Prep",[90],"2007-10","2003-12",500,[2267,2268,2269],"Nausea","Vomiting","Abdominal Pain",[2247],{"trials":2272,"activeCount":109},[],{"intervention":2274,"totalTrials":132,"cells":2275},"duloxetine",{"EARLY_PHASE1":2276,"PHASE1":2278,"PHASE2":2280,"PHASE3":2282,"PHASE4":2284,"NA":2294},{"trials":2277,"activeCount":109},[],{"trials":2279,"activeCount":109},[],{"trials":2281,"activeCount":109},[],{"trials":2283,"activeCount":109},[],{"trials":2285,"activeCount":109},[2286],{"nctId":2287,"briefTitle":2288,"status":102,"phases":2289,"primaryCompletion":2290,"completion":2290,"start":2291,"enrollment":396,"conditions":2292,"interventions":2293},"NCT00443352","A Research Study Examining The Use Of Duloxetine In The Prevention Of Migraine Headache",[90],"2012-11","2007-08",[15],[2274],{"trials":2295,"activeCount":109},[],{"intervention":2297,"totalTrials":132,"cells":2298},"Ibuprofen",{"EARLY_PHASE1":2299,"PHASE1":2301,"PHASE2":2303,"PHASE3":2305,"PHASE4":2307,"NA":2320},{"trials":2300,"activeCount":109},[],{"trials":2302,"activeCount":109},[],{"trials":2304,"activeCount":109},[],{"trials":2306,"activeCount":109},[],{"trials":2308,"activeCount":109},[2309],{"nctId":2310,"briefTitle":2311,"status":102,"phases":2312,"primaryCompletion":2313,"completion":2314,"start":2315,"enrollment":2316,"conditions":2317,"interventions":2319},"NCT01230411","Pilot Study to Collect and Evaluate Data on the Use of IV* Ibuprofen in the Treatment of an Acute Migraine Attack",[90],"2017-06","2017-07","2011-06",44,[2318],"Episodic Migraine",[2297],{"trials":2321,"activeCount":109},[],{"intervention":2323,"totalTrials":132,"cells":2324},"Saline",{"EARLY_PHASE1":2325,"PHASE1":2327,"PHASE2":2329,"PHASE3":2331,"PHASE4":2333,"NA":2345},{"trials":2326,"activeCount":109},[],{"trials":2328,"activeCount":109},[],{"trials":2330,"activeCount":109},[],{"trials":2332,"activeCount":109},[],{"trials":2334,"activeCount":109},[2335],{"nctId":2336,"briefTitle":2337,"status":548,"phases":2338,"primaryCompletion":2339,"completion":2340,"start":2341,"enrollment":109,"conditions":2342,"interventions":2343},"NCT03159000","A Research Study of Greater Occipital Nerve Block as a Treatment for Acute Migraine Attacks",[90],"2017-12-31","2018-06-30","2017-05-01",[15],[2323,2344],"lidocaine\u002Fbupivacaine",{"trials":2346,"activeCount":109},[],{"intervention":2344,"totalTrials":132,"cells":2348},{"EARLY_PHASE1":2349,"PHASE1":2351,"PHASE2":2353,"PHASE3":2355,"PHASE4":2357,"NA":2363},{"trials":2350,"activeCount":109},[],{"trials":2352,"activeCount":109},[],{"trials":2354,"activeCount":109},[],{"trials":2356,"activeCount":109},[],{"trials":2358,"activeCount":109},[2359],{"nctId":2336,"briefTitle":2337,"status":548,"phases":2360,"primaryCompletion":2339,"completion":2340,"start":2341,"enrollment":109,"conditions":2361,"interventions":2362},[90],[15],[2323,2344],{"trials":2364,"activeCount":109},[],{"intervention":2366,"totalTrials":132,"cells":2367},"Vasopressin",{"EARLY_PHASE1":2368,"PHASE1":2370,"PHASE2":2372,"PHASE3":2374,"PHASE4":2376,"NA":2389},{"trials":2369,"activeCount":109},[],{"trials":2371,"activeCount":109},[],{"trials":2373,"activeCount":109},[],{"trials":2375,"activeCount":109},[],{"trials":2377,"activeCount":109},[2378],{"nctId":2379,"briefTitle":2380,"status":151,"phases":2381,"primaryCompletion":2382,"completion":2383,"start":2384,"enrollment":353,"conditions":2385,"interventions":2387},"NCT04602767","Low Dose Vasopressin vs Phenylephrine in Cardiac Surgery",[90],"2024-05-29","2024-10-01","2020-10-15",[2386],"Acute Kidney Injury",[2366,2388],"Phenylephrine",{"trials":2390,"activeCount":109},[],{"intervention":2388,"totalTrials":132,"cells":2392},{"EARLY_PHASE1":2393,"PHASE1":2395,"PHASE2":2397,"PHASE3":2399,"PHASE4":2401,"NA":2407},{"trials":2394,"activeCount":109},[],{"trials":2396,"activeCount":109},[],{"trials":2398,"activeCount":109},[],{"trials":2400,"activeCount":109},[],{"trials":2402,"activeCount":109},[2403],{"nctId":2379,"briefTitle":2380,"status":151,"phases":2404,"primaryCompletion":2382,"completion":2383,"start":2384,"enrollment":353,"conditions":2405,"interventions":2406},[90],[2386],[2366,2388],{"trials":2408,"activeCount":109},[],{"intervention":2410,"totalTrials":132,"cells":2411},"Daratumumab and Hyaluronidase-fihj",{"EARLY_PHASE1":2412,"PHASE1":2414,"PHASE2":2416,"PHASE3":2418,"PHASE4":2420,"NA":2431},{"trials":2413,"activeCount":109},[],{"trials":2415,"activeCount":109},[],{"trials":2417,"activeCount":109},[],{"trials":2419,"activeCount":109},[],{"trials":2421,"activeCount":109},[2422],{"nctId":2423,"briefTitle":2424,"status":102,"phases":2425,"primaryCompletion":2426,"completion":2426,"start":2427,"enrollment":1480,"conditions":2428,"interventions":2430},"NCT05511428","Home Based Daratumumab Administration for Patients With Multiple Myeloma",[90],"2024-05-22","2022-11-08",[2429],"Plasma Cell Myeloma",[2410],{"trials":2432,"activeCount":109},[],{"intervention":2434,"totalTrials":132,"cells":2435},"3D HI and SHI of UCA",{"EARLY_PHASE1":2436,"PHASE1":2438,"PHASE2":2440,"PHASE3":2442,"PHASE4":2444,"NA":2455},{"trials":2437,"activeCount":109},[],{"trials":2439,"activeCount":109},[],{"trials":2441,"activeCount":109},[],{"trials":2443,"activeCount":109},[],{"trials":2445,"activeCount":109},[2446],{"nctId":2447,"briefTitle":2448,"status":102,"phases":2449,"primaryCompletion":2450,"completion":2450,"start":2451,"enrollment":2452,"conditions":2453,"interventions":2454},"NCT01490892","Quantitative Subharmonic Breast Imaging",[90],"2019-04-05","2011-11",219,[26],[2434],{"trials":2456,"activeCount":109},[],{"intervention":2458,"totalTrials":132,"cells":2459},"Azithromycin 500 mg",{"EARLY_PHASE1":2460,"PHASE1":2462,"PHASE2":2464,"PHASE3":2466,"PHASE4":2468,"NA":2481},{"trials":2461,"activeCount":109},[],{"trials":2463,"activeCount":109},[],{"trials":2465,"activeCount":109},[],{"trials":2467,"activeCount":109},[],{"trials":2469,"activeCount":109},[2470],{"nctId":2471,"briefTitle":2472,"status":102,"phases":2473,"primaryCompletion":2474,"completion":2475,"start":2476,"enrollment":27,"conditions":2477,"interventions":2479},"NCT04294069","Azithromycin Dose and PPROM Treatment: a Pilot Randomized Controlled Trial",[90],"2020-12-27","2021-04-01","2020-09-14",[2478],"Preterm Premature Rupture of Membrane",[2458,2480],"Azithromycin Oral Product",{"trials":2482,"activeCount":109},[],{"intervention":2480,"totalTrials":132,"cells":2484},{"EARLY_PHASE1":2485,"PHASE1":2487,"PHASE2":2489,"PHASE3":2491,"PHASE4":2493,"NA":2499},{"trials":2486,"activeCount":109},[],{"trials":2488,"activeCount":109},[],{"trials":2490,"activeCount":109},[],{"trials":2492,"activeCount":109},[],{"trials":2494,"activeCount":109},[2495],{"nctId":2471,"briefTitle":2472,"status":102,"phases":2496,"primaryCompletion":2474,"completion":2475,"start":2476,"enrollment":27,"conditions":2497,"interventions":2498},[90],[2478],[2458,2480],{"trials":2500,"activeCount":109},[],{"intervention":2502,"totalTrials":95,"cells":2503},"oral morphine",{"EARLY_PHASE1":2504,"PHASE1":2506,"PHASE2":2518,"PHASE3":2520,"PHASE4":2528,"NA":2530},{"trials":2505,"activeCount":109},[],{"trials":2507,"activeCount":109},[2508],{"nctId":2509,"briefTitle":2510,"status":102,"phases":2511,"primaryCompletion":1704,"completion":1704,"start":2512,"enrollment":2513,"conditions":2514,"interventions":2516},"NCT01671410","Buprenorphine for Treatment of Neonatal Abstinence Syndrome in Infants With In Utero Exposure to Benzodiazepines",[87],"2012-08",11,[2515],"Neonatal Abstinence Syndrome",[2502,2517],"sublingual buprenorphine",{"trials":2519,"activeCount":109},[],{"trials":2521,"activeCount":109},[2522],{"nctId":2523,"briefTitle":2524,"status":102,"phases":2525,"primaryCompletion":1777,"completion":1777,"start":2451,"enrollment":488,"conditions":2526,"interventions":2527},"NCT01452789","Blinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence Syndrome",[89],[2515],[2517,2502],{"trials":2529,"activeCount":109},[],{"trials":2531,"activeCount":109},[],{"intervention":2517,"totalTrials":95,"cells":2533},{"EARLY_PHASE1":2534,"PHASE1":2536,"PHASE2":2542,"PHASE3":2544,"PHASE4":2550,"NA":2552},{"trials":2535,"activeCount":109},[],{"trials":2537,"activeCount":109},[2538],{"nctId":2509,"briefTitle":2510,"status":102,"phases":2539,"primaryCompletion":1704,"completion":1704,"start":2512,"enrollment":2513,"conditions":2540,"interventions":2541},[87],[2515],[2502,2517],{"trials":2543,"activeCount":109},[],{"trials":2545,"activeCount":109},[2546],{"nctId":2523,"briefTitle":2524,"status":102,"phases":2547,"primaryCompletion":1777,"completion":1777,"start":2451,"enrollment":488,"conditions":2548,"interventions":2549},[89],[2515],[2517,2502],{"trials":2551,"activeCount":109},[],{"trials":2553,"activeCount":109},[],{"intervention":2555,"totalTrials":132,"cells":2556},"paricalcitol",{"EARLY_PHASE1":2557,"PHASE1":2559,"PHASE2":2561,"PHASE3":2563,"PHASE4":2577,"NA":2579},{"trials":2558,"activeCount":109},[],{"trials":2560,"activeCount":109},[],{"trials":2562,"activeCount":109},[],{"trials":2564,"activeCount":109},[2565],{"nctId":2566,"briefTitle":2567,"status":1775,"phases":2568,"primaryCompletion":2569,"completion":2569,"start":2570,"enrollment":1187,"conditions":2571,"interventions":2576},"NCT01012414","Effect of Vitamin D Supplement on Inflammation Markers in High-Risk Cardiovascular Patients With Chronic Kidney Disease",[89],"2011-05","2010-01",[2572,2573,2574,2575],"Coronary Artery Disease","Chronic Kidney Disease","Hypovitaminosis D","Secondary Hyperparathyroidism",[2555],{"trials":2578,"activeCount":109},[],{"trials":2580,"activeCount":109},[],{"intervention":2582,"totalTrials":132,"cells":2583},"estrogen",{"EARLY_PHASE1":2584,"PHASE1":2586,"PHASE2":2588,"PHASE3":2590,"PHASE4":2603,"NA":2605},{"trials":2585,"activeCount":109},[],{"trials":2587,"activeCount":109},[],{"trials":2589,"activeCount":109},[],{"trials":2591,"activeCount":109},[2592],{"nctId":2593,"briefTitle":2594,"status":102,"phases":2595,"primaryCompletion":2020,"completion":2596,"start":2597,"enrollment":2598,"conditions":2599,"interventions":2601},"NCT00029159","The Effect of Androgen and Growth Hormone on Height and Learning in Girls With Turner Syndrome",[89],"2012-06","1992-11",200,[2600],"Turner Syndrome",[2582,2602],"androgen",{"trials":2604,"activeCount":109},[],{"trials":2606,"activeCount":109},[],{"intervention":2602,"totalTrials":132,"cells":2608},{"EARLY_PHASE1":2609,"PHASE1":2611,"PHASE2":2613,"PHASE3":2615,"PHASE4":2621,"NA":2623},{"trials":2610,"activeCount":109},[],{"trials":2612,"activeCount":109},[],{"trials":2614,"activeCount":109},[],{"trials":2616,"activeCount":109},[2617],{"nctId":2593,"briefTitle":2594,"status":102,"phases":2618,"primaryCompletion":2020,"completion":2596,"start":2597,"enrollment":2598,"conditions":2619,"interventions":2620},[89],[2600],[2582,2602],{"trials":2622,"activeCount":109},[],{"trials":2624,"activeCount":109},[],{"intervention":2626,"totalTrials":132,"cells":2627},"Zoledronic acid",{"EARLY_PHASE1":2628,"PHASE1":2630,"PHASE2":2632,"PHASE3":2634,"PHASE4":2647,"NA":2649},{"trials":2629,"activeCount":109},[],{"trials":2631,"activeCount":109},[],{"trials":2633,"activeCount":109},[],{"trials":2635,"activeCount":109},[2636],{"nctId":2637,"briefTitle":2638,"status":102,"phases":2639,"primaryCompletion":2640,"completion":2640,"start":2641,"enrollment":2642,"conditions":2643,"interventions":2645},"NCT01642901","Zoledronic Acid in Acute Spinal Cord Injury",[89],"2018-03","2012-09",16,[2644],"Spinal Cord Injury",[2626,2646],"normal saline 0.9%",{"trials":2648,"activeCount":109},[],{"trials":2650,"activeCount":109},[],{"intervention":2646,"totalTrials":132,"cells":2652},{"EARLY_PHASE1":2653,"PHASE1":2655,"PHASE2":2657,"PHASE3":2659,"PHASE4":2665,"NA":2667},{"trials":2654,"activeCount":109},[],{"trials":2656,"activeCount":109},[],{"trials":2658,"activeCount":109},[],{"trials":2660,"activeCount":109},[2661],{"nctId":2637,"briefTitle":2638,"status":102,"phases":2662,"primaryCompletion":2640,"completion":2640,"start":2641,"enrollment":2642,"conditions":2663,"interventions":2664},[89],[2644],[2626,2646],{"trials":2666,"activeCount":109},[],{"trials":2668,"activeCount":109},[],{"intervention":2670,"totalTrials":132,"cells":2671},"IV magnesium sulfate",{"EARLY_PHASE1":2672,"PHASE1":2674,"PHASE2":2676,"PHASE3":2678,"PHASE4":2690,"NA":2692},{"trials":2673,"activeCount":109},[],{"trials":2675,"activeCount":109},[],{"trials":2677,"activeCount":109},[],{"trials":2679,"activeCount":109},[2680],{"nctId":2681,"briefTitle":2682,"status":151,"phases":2683,"primaryCompletion":2684,"completion":2684,"start":2685,"enrollment":410,"conditions":2686,"interventions":2689},"NCT05049707","Does Perioperative Intravenous Magnesium Affect Postoperative Quality of Recovery in Craniotomy Surgery Patients?",[89],"2025-10-01","2024-11-01",[2687,2688],"Brain Tumor","Surgery",[2670],{"trials":2691,"activeCount":109},[],{"trials":2693,"activeCount":109},[],{"intervention":2695,"totalTrials":132,"cells":2696},"nebivolol",{"EARLY_PHASE1":2697,"PHASE1":2699,"PHASE2":2701,"PHASE3":2703,"PHASE4":2717,"NA":2719},{"trials":2698,"activeCount":109},[],{"trials":2700,"activeCount":109},[],{"trials":2702,"activeCount":109},[],{"trials":2704,"activeCount":109},[2705],{"nctId":2706,"briefTitle":2707,"status":102,"phases":2708,"primaryCompletion":2709,"completion":2709,"start":2710,"enrollment":2711,"conditions":2712,"interventions":2715},"NCT01499134","Comparison of 2 Beta Blocker Drugs on Peripheral Arterial Disease in Patients With High Blood Pressure",[89],"2014-06","2011-08",17,[2713,2714],"Peripheral Artery Disease","Hypertension",[2695,2716],"Metoprolol succinate",{"trials":2718,"activeCount":109},[],{"trials":2720,"activeCount":109},[],{"intervention":2716,"totalTrials":132,"cells":2722},{"EARLY_PHASE1":2723,"PHASE1":2725,"PHASE2":2727,"PHASE3":2729,"PHASE4":2735,"NA":2737},{"trials":2724,"activeCount":109},[],{"trials":2726,"activeCount":109},[],{"trials":2728,"activeCount":109},[],{"trials":2730,"activeCount":109},[2731],{"nctId":2706,"briefTitle":2707,"status":102,"phases":2732,"primaryCompletion":2709,"completion":2709,"start":2710,"enrollment":2711,"conditions":2733,"interventions":2734},[89],[2713,2714],[2695,2716],{"trials":2736,"activeCount":109},[],{"trials":2738,"activeCount":109},[],{"intervention":2740,"totalTrials":132,"cells":2741},"IV Medications",{"EARLY_PHASE1":2742,"PHASE1":2744,"PHASE2":2746,"PHASE3":2748,"PHASE4":2761,"NA":2763},{"trials":2743,"activeCount":109},[],{"trials":2745,"activeCount":109},[],{"trials":2747,"activeCount":109},[],{"trials":2749,"activeCount":109},[2750],{"nctId":2751,"briefTitle":2752,"status":102,"phases":2753,"primaryCompletion":2754,"completion":2754,"start":2755,"enrollment":2756,"conditions":2757,"interventions":2760},"NCT05021263","Does IV Magnesium Improve Quality of Recovery With ERAS Protocols in Laparoscopic Colorectal Surgery?",[89],"2023-12-29","2022-05-27",90,[2758,2759],"Colo-rectal Cancer","Anesthesia",[2740],{"trials":2762,"activeCount":109},[],{"trials":2764,"activeCount":109},[],{"intervention":2766,"totalTrials":458,"cells":2767},"Ascorbic Acid",{"EARLY_PHASE1":2768,"PHASE1":2770,"PHASE2":2772,"PHASE3":2803,"PHASE4":2805,"NA":2807},{"trials":2769,"activeCount":109},[],{"trials":2771,"activeCount":109},[],{"trials":2773,"activeCount":109},[2774,2784,2793],{"nctId":2775,"briefTitle":2776,"status":1775,"phases":2777,"primaryCompletion":2778,"completion":2778,"start":2779,"enrollment":1177,"conditions":2780,"interventions":2782},"NCT01550510","Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA",[87,88],"2015-02","2011-12",[2781],"Stage IV Colorectal Cancer",[2766,2783],"Irinotecan",{"nctId":2785,"briefTitle":2786,"status":1775,"phases":2787,"primaryCompletion":2788,"completion":2788,"start":2789,"enrollment":2513,"conditions":2790,"interventions":2792},"NCT01555489","Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca",[88],"2016-01","2011-10",[2791],"Stage IV Pancreatic Cancer",[2766],{"nctId":2794,"briefTitle":2795,"status":151,"phases":2796,"primaryCompletion":2797,"completion":2797,"start":2798,"enrollment":2799,"conditions":2800,"interventions":2802},"NCT04363216","Pharmacologic Ascorbic Acid as an Activator of Lymphocyte Signaling for COVID-19 Treatment",[88],"2021-05","2020-05",66,[2801],"COVID-19",[2766],{"trials":2804,"activeCount":109},[],{"trials":2806,"activeCount":109},[],{"trials":2808,"activeCount":109},[],{"intervention":2810,"totalTrials":95,"cells":2811},"Everolimus",{"EARLY_PHASE1":2812,"PHASE1":2814,"PHASE2":2816,"PHASE3":2840,"PHASE4":2842,"NA":2844},{"trials":2813,"activeCount":109},[],{"trials":2815,"activeCount":109},[],{"trials":2817,"activeCount":109},[2818,2830],{"nctId":2819,"briefTitle":2820,"status":151,"phases":2821,"primaryCompletion":2822,"completion":2823,"start":2824,"enrollment":2825,"conditions":2826,"interventions":2828},"NCT01263951","Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone",[88],"2021-02-01","2022-05","2010-11",35,[2827],"Differentiated Thyroid Cancer",[2810,2829],"Sorafenib",{"nctId":2831,"briefTitle":2832,"status":1737,"phases":2833,"primaryCompletion":2834,"completion":2834,"start":2835,"enrollment":30,"conditions":2836,"interventions":2838},"NCT03139747","UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone",[88],"2022-05-30","2017-04-03",[2837],"Thyroid Cancer",[2839,2810],"Lenvatinib",{"trials":2841,"activeCount":109},[],{"trials":2843,"activeCount":109},[],{"trials":2845,"activeCount":109},[],{"intervention":2829,"totalTrials":95,"cells":2847},{"EARLY_PHASE1":2848,"PHASE1":2850,"PHASE2":2852,"PHASE3":2867,"PHASE4":2869,"NA":2871},{"trials":2849,"activeCount":109},[],{"trials":2851,"activeCount":109},[],{"trials":2853,"activeCount":109},[2854,2858],{"nctId":2819,"briefTitle":2820,"status":151,"phases":2855,"primaryCompletion":2822,"completion":2823,"start":2824,"enrollment":2825,"conditions":2856,"interventions":2857},[88],[2827],[2810,2829],{"nctId":2859,"briefTitle":2860,"status":102,"phases":2861,"primaryCompletion":2788,"completion":2788,"start":2641,"enrollment":30,"conditions":2862,"interventions":2865},"NCT01754987","A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective",[87,88],[2863,2864],"Metastatic Hepatocellular Carcinoma","Advanced Liver Cancer",[2866,2829],"Ascorbic Acid + Sorafenib",{"trials":2868,"activeCount":109},[],{"trials":2870,"activeCount":109},[],{"trials":2872,"activeCount":109},[],{"intervention":2874,"totalTrials":95,"cells":2875},"Perflutren Protein-Type A Microspheres",{"EARLY_PHASE1":2876,"PHASE1":2878,"PHASE2":2880,"PHASE3":2901,"PHASE4":2903,"NA":2905},{"trials":2877,"activeCount":109},[],{"trials":2879,"activeCount":109},[],{"trials":2881,"activeCount":109},[2882,2890],{"nctId":2883,"briefTitle":2884,"status":102,"phases":2885,"primaryCompletion":338,"completion":74,"start":2886,"enrollment":2642,"conditions":2887,"interventions":2889},"NCT05328167","Contrast-Enhanced Ultrasound for the Prediction of Bile Duct Cancer Response to Radioembolization Treatment",[88],"2021-12-14",[2888],"Intrahepatic Cholangiocarcinoma",[2874],{"nctId":2891,"briefTitle":2892,"status":102,"phases":2893,"primaryCompletion":2894,"completion":2895,"start":2896,"enrollment":2897,"conditions":2898,"interventions":2900},"NCT03199274","Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer",[88],"2024-02-27","2025-01-23","2017-07-01",104,[2899],"Hepatocellular Carcinoma",[2874],{"trials":2902,"activeCount":109},[],{"trials":2904,"activeCount":109},[],{"trials":2906,"activeCount":109},[],{"intervention":2908,"totalTrials":95,"cells":2909},"buprenorphine",{"EARLY_PHASE1":2910,"PHASE1":2912,"PHASE2":2922,"PHASE3":2934,"PHASE4":2936,"NA":2938},{"trials":2911,"activeCount":109},[],{"trials":2913,"activeCount":109},[2914],{"nctId":2915,"briefTitle":2916,"status":102,"phases":2917,"primaryCompletion":2570,"completion":2570,"start":2918,"enrollment":11,"conditions":2919,"interventions":2920},"NCT00521248","Buprenorphine for the Treatment of Neonatal Abstinence Syndrome",[87],"2004-04",[2515],[2908,2921],"Oral morphine solution",{"trials":2923,"activeCount":109},[2924],{"nctId":2925,"briefTitle":2926,"status":102,"phases":2927,"primaryCompletion":2928,"completion":2928,"start":2929,"enrollment":1187,"conditions":2930,"interventions":2932},"NCT03608696","Buprenorphine Pharmacometric Open Label Research Study of Drug Exposure",[87,88],"2019-07-11","2018-08-29",[2515,2931],"Neonatal Opiate Withdrawal Syndrome",[2933],"Buprenorphine",{"trials":2935,"activeCount":109},[],{"trials":2937,"activeCount":109},[],{"trials":2939,"activeCount":109},[],{"intervention":2941,"totalTrials":132,"cells":2942},"indomethacin",{"EARLY_PHASE1":2943,"PHASE1":2945,"PHASE2":2947,"PHASE3":2960,"PHASE4":2962,"NA":2964},{"trials":2944,"activeCount":109},[],{"trials":2946,"activeCount":109},[],{"trials":2948,"activeCount":109},[2949],{"nctId":2950,"briefTitle":2951,"status":151,"phases":2952,"primaryCompletion":2953,"completion":2954,"start":2955,"enrollment":2956,"conditions":2957,"interventions":2959},"NCT00466128","Indomethacin Versus Placebo in Women With Preterm Premature Rupture of Membranes (PPROM)",[88],"2015-04","2016-04","2007-04",116,[2958],"Preterm Premature Rupture of Membranes",[2941],{"trials":2961,"activeCount":109},[],{"trials":2963,"activeCount":109},[],{"trials":2965,"activeCount":109},[],{"intervention":2967,"totalTrials":132,"cells":2968},"Exenatide 0.27 ng\u002Fkg\u002Fmin",{"EARLY_PHASE1":2969,"PHASE1":2971,"PHASE2":2973,"PHASE3":2985,"PHASE4":2987,"NA":2989},{"trials":2970,"activeCount":109},[],{"trials":2972,"activeCount":109},[],{"trials":2974,"activeCount":109},[2975],{"nctId":2976,"briefTitle":2977,"status":102,"phases":2978,"primaryCompletion":2954,"completion":2954,"start":2979,"enrollment":2897,"conditions":2980,"interventions":2983},"NCT00882050","Intravenous Exenatide (Byetta) During Surgery",[87,88],"2009-03",[2981,2982,417],"Euglycemia","Hypoglycemia",[2967,2984],"Exenatide 0.41 ng\u002Fkg\u002Fmin",{"trials":2986,"activeCount":109},[],{"trials":2988,"activeCount":109},[],{"trials":2990,"activeCount":109},[],{"intervention":2984,"totalTrials":132,"cells":2992},{"EARLY_PHASE1":2993,"PHASE1":2995,"PHASE2":2997,"PHASE3":3003,"PHASE4":3005,"NA":3007},{"trials":2994,"activeCount":109},[],{"trials":2996,"activeCount":109},[],{"trials":2998,"activeCount":109},[2999],{"nctId":2976,"briefTitle":2977,"status":102,"phases":3000,"primaryCompletion":2954,"completion":2954,"start":2979,"enrollment":2897,"conditions":3001,"interventions":3002},[87,88],[2981,2982,417],[2967,2984],{"trials":3004,"activeCount":109},[],{"trials":3006,"activeCount":109},[],{"trials":3008,"activeCount":109},[],{"intervention":2783,"totalTrials":132,"cells":3010},{"EARLY_PHASE1":3011,"PHASE1":3013,"PHASE2":3015,"PHASE3":3021,"PHASE4":3023,"NA":3025},{"trials":3012,"activeCount":109},[],{"trials":3014,"activeCount":109},[],{"trials":3016,"activeCount":109},[3017],{"nctId":2775,"briefTitle":2776,"status":1775,"phases":3018,"primaryCompletion":2778,"completion":2778,"start":2779,"enrollment":1177,"conditions":3019,"interventions":3020},[87,88],[2781],[2766,2783],{"trials":3022,"activeCount":109},[],{"trials":3024,"activeCount":109},[],{"trials":3026,"activeCount":109},[],{"intervention":2839,"totalTrials":132,"cells":3028},{"EARLY_PHASE1":3029,"PHASE1":3031,"PHASE2":3033,"PHASE3":3039,"PHASE4":3041,"NA":3043},{"trials":3030,"activeCount":109},[],{"trials":3032,"activeCount":109},[],{"trials":3034,"activeCount":109},[3035],{"nctId":2831,"briefTitle":2832,"status":1737,"phases":3036,"primaryCompletion":2834,"completion":2834,"start":2835,"enrollment":30,"conditions":3037,"interventions":3038},[88],[2837],[2839,2810],{"trials":3040,"activeCount":109},[],{"trials":3042,"activeCount":109},[],{"trials":3044,"activeCount":109},[],{"intervention":3046,"totalTrials":132,"cells":3047},"Perflutren Lipid Microsphere Intravenous Suspension",{"EARLY_PHASE1":3048,"PHASE1":3050,"PHASE2":3052,"PHASE3":3065,"PHASE4":3067,"NA":3069},{"trials":3049,"activeCount":109},[],{"trials":3051,"activeCount":109},[],{"trials":3053,"activeCount":109},[3054],{"nctId":3055,"briefTitle":3056,"status":102,"phases":3057,"primaryCompletion":3058,"completion":3059,"start":3060,"enrollment":3061,"conditions":3062,"interventions":3064},"NCT02967458","Detection of High Grade Prostate Cancer With Subharmonic Ultrasound Imaging, A Pilot Study",[88],"2018-02-01","2018-09-20","2017-02-01",55,[3063],"Prostatic Neoplasm",[3046],{"trials":3066,"activeCount":109},[],{"trials":3068,"activeCount":109},[],{"trials":3070,"activeCount":109},[],{"intervention":3072,"totalTrials":132,"cells":3073},"NitroBid",{"EARLY_PHASE1":3074,"PHASE1":3076,"PHASE2":3078,"PHASE3":3090,"PHASE4":3092,"NA":3094},{"trials":3075,"activeCount":109},[],{"trials":3077,"activeCount":109},[],{"trials":3079,"activeCount":109},[3080],{"nctId":3081,"briefTitle":3082,"status":151,"phases":3083,"primaryCompletion":3084,"completion":3085,"start":3086,"enrollment":3087,"conditions":3088,"interventions":3089},"NCT06289946","Topical Nitro or Placebo Pre-Cath",[88],"2025-03-01","2025-03-31","2024-03-01",256,[2572],[3072],{"trials":3091,"activeCount":109},[],{"trials":3093,"activeCount":109},[],{"trials":3095,"activeCount":109},[],{"intervention":3097,"totalTrials":132,"cells":3098},"Convalescent Plasma",{"EARLY_PHASE1":3099,"PHASE1":3101,"PHASE2":3103,"PHASE3":3115,"PHASE4":3117,"NA":3119},{"trials":3100,"activeCount":109},[],{"trials":3102,"activeCount":109},[],{"trials":3104,"activeCount":109},[3105],{"nctId":3106,"briefTitle":3107,"status":102,"phases":3108,"primaryCompletion":3109,"completion":3110,"start":3111,"enrollment":3112,"conditions":3113,"interventions":3114},"NCT04389710","Convalescent Plasma for the Treatment of COVID-19",[88],"2020-11-03","2020-12-07","2020-04-15",52,[2801],[3097],{"trials":3116,"activeCount":109},[],{"trials":3118,"activeCount":109},[],{"trials":3120,"activeCount":109},[],{"intervention":3122,"totalTrials":132,"cells":3123},"Incobotulinumtoxina",{"EARLY_PHASE1":3124,"PHASE1":3126,"PHASE2":3128,"PHASE3":3140,"PHASE4":3142,"NA":3144},{"trials":3125,"activeCount":109},[],{"trials":3127,"activeCount":109},[],{"trials":3129,"activeCount":109},[3130],{"nctId":3131,"briefTitle":3132,"status":1775,"phases":3133,"primaryCompletion":3134,"completion":3135,"start":3136,"enrollment":27,"conditions":3137,"interventions":3139},"NCT02088632","Incobotulinum Toxin for the Treatment of Trigeminal Neuralgia",[88],"2015-06-11","2016-10-19","2014-03-14",[3138],"Trigeminal Neuralgia",[3122],{"trials":3141,"activeCount":109},[],{"trials":3143,"activeCount":109},[],{"trials":3145,"activeCount":109},[],{"intervention":3147,"totalTrials":132,"cells":3148},"Aspirin 81Mg Non-enteric coated Tab",{"EARLY_PHASE1":3149,"PHASE1":3151,"PHASE2":3153,"PHASE3":3164,"PHASE4":3166,"NA":3168},{"trials":3150,"activeCount":109},[],{"trials":3152,"activeCount":109},[],{"trials":3154,"activeCount":109},[3155],{"nctId":3156,"briefTitle":3157,"status":102,"phases":3158,"primaryCompletion":3159,"completion":3160,"start":3161,"enrollment":1480,"conditions":3162,"interventions":3163},"NCT04645004","Antenatal Platelet Response on Aspirin: a Pharmacokinetic Study Through Pregnancy",[87,88],"2024-01-11","2024-03-15","2020-12-29",[862],[3147],{"trials":3165,"activeCount":109},[],{"trials":3167,"activeCount":109},[],{"trials":3169,"activeCount":109},[],{"intervention":3171,"totalTrials":132,"cells":3172},"HTS 3%",{"EARLY_PHASE1":3173,"PHASE1":3175,"PHASE2":3177,"PHASE3":3191,"PHASE4":3193,"NA":3195},{"trials":3174,"activeCount":109},[],{"trials":3176,"activeCount":109},[],{"trials":3178,"activeCount":109},[3179],{"nctId":3180,"briefTitle":3181,"status":151,"phases":3182,"primaryCompletion":3183,"start":3184,"enrollment":126,"conditions":3185,"interventions":3189},"NCT02432157","Safety and Feasibility of Hypertonic Saline Solution After Aneurysmal Subarachnoid Hemorrhage:",[87,88],"2017-01","2015-01",[3186,3187,3188],"Subarachnoid Hemorrhage","Cerebral Vasospasm","Hyponatremia",[3171,3190],"Standard fluid management",{"trials":3192,"activeCount":109},[],{"trials":3194,"activeCount":109},[],{"trials":3196,"activeCount":109},[],{"intervention":3190,"totalTrials":132,"cells":3198},{"EARLY_PHASE1":3199,"PHASE1":3201,"PHASE2":3203,"PHASE3":3209,"PHASE4":3211,"NA":3213},{"trials":3200,"activeCount":109},[],{"trials":3202,"activeCount":109},[],{"trials":3204,"activeCount":109},[3205],{"nctId":3180,"briefTitle":3181,"status":151,"phases":3206,"primaryCompletion":3183,"start":3184,"enrollment":126,"conditions":3207,"interventions":3208},[87,88],[3186,3187,3188],[3171,3190],{"trials":3210,"activeCount":109},[],{"trials":3212,"activeCount":109},[],{"trials":3214,"activeCount":109},[],{"intervention":3216,"totalTrials":132,"cells":3217},"3% NaCl Solution",{"EARLY_PHASE1":3218,"PHASE1":3220,"PHASE2":3222,"PHASE3":3234,"PHASE4":3236,"NA":3238},{"trials":3219,"activeCount":109},[],{"trials":3221,"activeCount":109},[],{"trials":3223,"activeCount":109},[3224],{"nctId":3225,"briefTitle":3226,"status":151,"phases":3227,"primaryCompletion":2069,"completion":3228,"start":2569,"enrollment":3229,"conditions":3230,"interventions":3232},"NCT01428050","The Use of a Restrictive Fluid Regimen With Hypertonic Saline for Patients Undergoing Pancreaticoduodenectomy",[88],"2015-12",264,[3231],"Pancreaticoduodenectomy",[3216,3233],"Lactated Ringers Solution",{"trials":3235,"activeCount":109},[],{"trials":3237,"activeCount":109},[],{"trials":3239,"activeCount":109},[],{"intervention":3233,"totalTrials":132,"cells":3241},{"EARLY_PHASE1":3242,"PHASE1":3244,"PHASE2":3246,"PHASE3":3252,"PHASE4":3254,"NA":3256},{"trials":3243,"activeCount":109},[],{"trials":3245,"activeCount":109},[],{"trials":3247,"activeCount":109},[3248],{"nctId":3225,"briefTitle":3226,"status":151,"phases":3249,"primaryCompletion":2069,"completion":3228,"start":2569,"enrollment":3229,"conditions":3250,"interventions":3251},[88],[3231],[3216,3233],{"trials":3253,"activeCount":109},[],{"trials":3255,"activeCount":109},[],{"trials":3257,"activeCount":109},[],{"intervention":2866,"totalTrials":132,"cells":3259},{"EARLY_PHASE1":3260,"PHASE1":3262,"PHASE2":3264,"PHASE3":3270,"PHASE4":3272,"NA":3274},{"trials":3261,"activeCount":109},[],{"trials":3263,"activeCount":109},[],{"trials":3265,"activeCount":109},[3266],{"nctId":2859,"briefTitle":2860,"status":102,"phases":3267,"primaryCompletion":2788,"completion":2788,"start":2641,"enrollment":30,"conditions":3268,"interventions":3269},[87,88],[2863,2864],[2866,2829],{"trials":3271,"activeCount":109},[],{"trials":3273,"activeCount":109},[],{"trials":3275,"activeCount":109},[],{"intervention":3277,"totalTrials":132,"cells":3278},"Cabozantinib",{"EARLY_PHASE1":3279,"PHASE1":3281,"PHASE2":3283,"PHASE3":3294,"PHASE4":3296,"NA":3298},{"trials":3280,"activeCount":109},[],{"trials":3282,"activeCount":109},[],{"trials":3284,"activeCount":109},[3285],{"nctId":3286,"briefTitle":3287,"status":151,"phases":3288,"primaryCompletion":2823,"completion":2823,"start":1977,"enrollment":3289,"conditions":3290,"interventions":3293},"NCT02041260","A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting",[88],43,[3291,3292],"Differentiated Thyroid Cancer (DTC)","Poorly Differentiated Thyroid Cancer",[3277],{"trials":3295,"activeCount":109},[],{"trials":3297,"activeCount":109},[],{"trials":3299,"activeCount":109},[],{"intervention":3301,"totalTrials":132,"cells":3302},"mechlorethamine gel 0.016%",{"EARLY_PHASE1":3303,"PHASE1":3305,"PHASE2":3307,"PHASE3":3319,"PHASE4":3321,"NA":3323},{"trials":3304,"activeCount":109},[],{"trials":3306,"activeCount":109},[],{"trials":3308,"activeCount":109},[3309],{"nctId":3310,"briefTitle":3311,"status":151,"phases":3312,"primaryCompletion":3313,"start":1704,"enrollment":3314,"conditions":3315,"interventions":3318},"NCT02881749","Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides",[88],"2020-08",68,[3316,3317],"Mycosis Fungoides","Cutaneous T-cell Lymphoma",[3301],{"trials":3320,"activeCount":109},[],{"trials":3322,"activeCount":109},[],{"trials":3324,"activeCount":109},[],{"intervention":3326,"totalTrials":132,"cells":3327},"Defactinib Hydrochloride",{"EARLY_PHASE1":3328,"PHASE1":3330,"PHASE2":3332,"PHASE3":3344,"PHASE4":3346,"NA":3348},{"trials":3329,"activeCount":109},[],{"trials":3331,"activeCount":109},[],{"trials":3333,"activeCount":109},[3334],{"nctId":3335,"briefTitle":3336,"status":1775,"phases":3337,"primaryCompletion":3338,"completion":3338,"start":3339,"enrollment":3340,"conditions":3341,"interventions":3342},"NCT04720417","Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma",[88],"2024-04-30","2021-01-26",13,[446],[3326,3343],"Raf\u002FMEK Inhibitor VS-6766",{"trials":3345,"activeCount":109},[],{"trials":3347,"activeCount":109},[],{"trials":3349,"activeCount":109},[],{"intervention":3343,"totalTrials":132,"cells":3351},{"EARLY_PHASE1":3352,"PHASE1":3354,"PHASE2":3356,"PHASE3":3362,"PHASE4":3364,"NA":3366},{"trials":3353,"activeCount":109},[],{"trials":3355,"activeCount":109},[],{"trials":3357,"activeCount":109},[3358],{"nctId":3335,"briefTitle":3336,"status":1775,"phases":3359,"primaryCompletion":3338,"completion":3338,"start":3339,"enrollment":3340,"conditions":3360,"interventions":3361},[88],[446],[3326,3343],{"trials":3363,"activeCount":109},[],{"trials":3365,"activeCount":109},[],{"trials":3367,"activeCount":109},[],{"intervention":3369,"totalTrials":132,"cells":3370},"Optison",{"EARLY_PHASE1":3371,"PHASE1":3373,"PHASE2":3375,"PHASE3":3388,"PHASE4":3390,"NA":3392},{"trials":3372,"activeCount":109},[],{"trials":3374,"activeCount":109},[],{"trials":3376,"activeCount":109},[3377],{"nctId":3378,"briefTitle":3379,"status":102,"phases":3380,"primaryCompletion":3381,"completion":3382,"start":3383,"enrollment":3384,"conditions":3385,"interventions":3387},"NCT02440334","Two and Three Dimensional Contrast-enhanced Ultrasound for Screening of Renal Cell Carcinoma Recurrence Following Cryoablation",[88],"2017-12","2018-06-21","2015-04-23",53,[3386],"Renal Cell Carcinoma",[3369],{"trials":3389,"activeCount":109},[],{"trials":3391,"activeCount":109},[],{"trials":3393,"activeCount":109},[],{"intervention":560,"totalTrials":132,"cells":3395},{"EARLY_PHASE1":3396,"PHASE1":3398,"PHASE2":3400,"PHASE3":3406,"PHASE4":3408,"NA":3410},{"trials":3397,"activeCount":109},[],{"trials":3399,"activeCount":109},[],{"trials":3401,"activeCount":109},[3402],{"nctId":546,"briefTitle":547,"status":548,"phases":3403,"primaryCompletion":550,"completion":551,"start":552,"enrollment":109,"conditions":3404,"interventions":3405},[87,88],[554,555,556,557,558],[509,560,561,562],{"trials":3407,"activeCount":109},[],{"trials":3409,"activeCount":109},[],{"trials":3411,"activeCount":109},[],{"intervention":562,"totalTrials":132,"cells":3413},{"EARLY_PHASE1":3414,"PHASE1":3416,"PHASE2":3418,"PHASE3":3424,"PHASE4":3426,"NA":3428},{"trials":3415,"activeCount":109},[],{"trials":3417,"activeCount":109},[],{"trials":3419,"activeCount":109},[3420],{"nctId":546,"briefTitle":547,"status":548,"phases":3421,"primaryCompletion":550,"completion":551,"start":552,"enrollment":109,"conditions":3422,"interventions":3423},[87,88],[554,555,556,557,558],[509,560,561,562],{"trials":3425,"activeCount":109},[],{"trials":3427,"activeCount":109},[],{"trials":3429,"activeCount":109},[],{"intervention":3431,"totalTrials":132,"cells":3432},"Sonazoid",{"EARLY_PHASE1":3433,"PHASE1":3435,"PHASE2":3437,"PHASE3":3448,"PHASE4":3450,"NA":3452},{"trials":3434,"activeCount":109},[],{"trials":3436,"activeCount":109},[],{"trials":3438,"activeCount":109},[3439],{"nctId":3440,"briefTitle":3441,"status":102,"phases":3442,"primaryCompletion":3443,"completion":3444,"start":3445,"enrollment":169,"conditions":3446,"interventions":3447},"NCT03245255","Noninvasive Real-time Intracardiac Pressure Measurements Using Subharmonic Ultrasound",[88],"2020-09-18","2023-06-07","2017-12-04",[1216,1217,1218,1219,21],[3431],{"trials":3449,"activeCount":109},[],{"trials":3451,"activeCount":109},[],{"trials":3453,"activeCount":109},[],{"intervention":3455,"totalTrials":132,"cells":3456},"Antiandrogen Therapy",{"EARLY_PHASE1":3457,"PHASE1":3459,"PHASE2":3461,"PHASE3":3475,"PHASE4":3477,"NA":3479},{"trials":3458,"activeCount":109},[],{"trials":3460,"activeCount":109},[],{"trials":3462,"activeCount":109},[3463],{"nctId":3464,"briefTitle":3465,"status":1775,"phases":3466,"primaryCompletion":3467,"completion":3468,"start":3469,"enrollment":27,"conditions":3470,"interventions":3474},"NCT05676463","MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer",[88],"2025-08-07","2025-10-24","2022-11-16",[3471,3472,3473],"Prostate Adenocarcinoma","Stage IIIB Prostate Cancer AJCC v8","Stage IIIC Prostate Cancer AJCC v8",[3455],{"trials":3476,"activeCount":109},[],{"trials":3478,"activeCount":109},[],{"trials":3480,"activeCount":109},[],{"intervention":3482,"totalTrials":132,"cells":3483},"androgen oxandrolone",{"EARLY_PHASE1":3484,"PHASE1":3486,"PHASE2":3488,"PHASE3":3499,"PHASE4":3501,"NA":3503},{"trials":3485,"activeCount":109},[],{"trials":3487,"activeCount":109},[],{"trials":3489,"activeCount":109},[3490],{"nctId":3491,"briefTitle":3492,"status":102,"phases":3493,"primaryCompletion":3494,"completion":3494,"start":3495,"enrollment":1715,"conditions":3496,"interventions":3498},"NCT00348946","Androgen Effect on Klinefelter Syndrome Motor Outcome",[88],"2017-11-30","2006-07",[3497],"Klinefelter Syndrome",[3482],{"trials":3500,"activeCount":109},[],{"trials":3502,"activeCount":109},[],{"trials":3504,"activeCount":109},[],{"intervention":3506,"totalTrials":132,"cells":3507},"elvucitabine",{"EARLY_PHASE1":3508,"PHASE1":3510,"PHASE2":3512,"PHASE3":3523,"PHASE4":3525,"NA":3527},{"trials":3509,"activeCount":109},[],{"trials":3511,"activeCount":109},[],{"trials":3513,"activeCount":109},[3514],{"nctId":3515,"briefTitle":3516,"status":102,"phases":3517,"primaryCompletion":3518,"completion":3518,"start":3519,"enrollment":30,"conditions":3520,"interventions":3522},"NCT00405249","Safety Study of Elvucitabine in HIV-1 Subjects",[88],"2006-11","2006-09",[3521],"HIV Infections",[3506],{"trials":3524,"activeCount":109},[],{"trials":3526,"activeCount":109},[],{"trials":3528,"activeCount":109},[],{"intervention":3530,"totalTrials":132,"cells":3531},"Furosemide",{"EARLY_PHASE1":3532,"PHASE1":3534,"PHASE2":3536,"PHASE3":3547,"PHASE4":3549,"NA":3551},{"trials":3533,"activeCount":109},[],{"trials":3535,"activeCount":109},[],{"trials":3537,"activeCount":109},[3538],{"nctId":3539,"briefTitle":3540,"status":1775,"phases":3541,"primaryCompletion":3542,"completion":3542,"start":3543,"enrollment":1534,"conditions":3544,"interventions":3546},"NCT03362515","Treatment of Post-Operative Sinonasal Polyposis With Topical Furosemide",[88],"2022-04-14","2017-12-01",[3545],"Nasal Polyps",[3530],{"trials":3548,"activeCount":109},[],{"trials":3550,"activeCount":109},[],{"trials":3552,"activeCount":109},[],{"intervention":3554,"totalTrials":132,"cells":3555},"GM1 ganglioside",{"EARLY_PHASE1":3556,"PHASE1":3558,"PHASE2":3560,"PHASE3":3571,"PHASE4":3573,"NA":3575},{"trials":3557,"activeCount":109},[],{"trials":3559,"activeCount":109},[],{"trials":3561,"activeCount":109},[3562],{"nctId":3563,"briefTitle":3564,"status":102,"phases":3565,"primaryCompletion":3566,"completion":3566,"start":3567,"enrollment":3568,"conditions":3569,"interventions":3570},"NCT00037830","GM1 Ganglioside Effects on Parkinson's Disease",[88],"2010-06","1999-11",94,[835],[3554],{"trials":3572,"activeCount":109},[],{"trials":3574,"activeCount":109},[],{"trials":3576,"activeCount":109},[],{"intervention":479,"totalTrials":458,"cells":3578},{"EARLY_PHASE1":3579,"PHASE1":3581,"PHASE2":3608,"PHASE3":3610,"PHASE4":3612,"NA":3614},{"trials":3580,"activeCount":109},[],{"trials":3582,"activeCount":109},[3583,3592,3604],{"nctId":3584,"briefTitle":3585,"status":102,"phases":3586,"primaryCompletion":2068,"completion":2068,"start":3587,"enrollment":471,"conditions":3588,"interventions":3590},"NCT02270918","Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate Kcentra",[87],"2014-11",[3589],"Thrombosis",[3591,479],"Kcentra",{"nctId":3593,"briefTitle":3594,"status":102,"phases":3595,"primaryCompletion":3596,"completion":3597,"start":3598,"enrollment":1177,"conditions":3599,"interventions":3603},"NCT04191928","Pharmacokinetics of Apixaban in Patients Undergoing Pancreaticoduodenectomy",[87],"2020-07-25","2021-09-01","2020-03-03",[3600,3601,3602],"Pancreas Cancer","DVT","Pulmonary Embolism",[479],{"nctId":465,"briefTitle":466,"status":102,"phases":3605,"primaryCompletion":468,"completion":469,"start":470,"enrollment":471,"conditions":3606,"interventions":3607},[87],[473,474,475],[477,478,457,479,479],{"trials":3609,"activeCount":109},[],{"trials":3611,"activeCount":109},[],{"trials":3613,"activeCount":109},[],{"trials":3615,"activeCount":109},[],{"intervention":3591,"totalTrials":132,"cells":3617},{"EARLY_PHASE1":3618,"PHASE1":3620,"PHASE2":3626,"PHASE3":3628,"PHASE4":3630,"NA":3632},{"trials":3619,"activeCount":109},[],{"trials":3621,"activeCount":109},[3622],{"nctId":3584,"briefTitle":3585,"status":102,"phases":3623,"primaryCompletion":2068,"completion":2068,"start":3587,"enrollment":471,"conditions":3624,"interventions":3625},[87],[3589],[3591,479],{"trials":3627,"activeCount":109},[],{"trials":3629,"activeCount":109},[],{"trials":3631,"activeCount":109},[],{"trials":3633,"activeCount":109},[],{"intervention":1277,"totalTrials":132,"cells":3635},{"EARLY_PHASE1":3636,"PHASE1":3638,"PHASE2":3644,"PHASE3":3646,"PHASE4":3648,"NA":3650},{"trials":3637,"activeCount":109},[],{"trials":3639,"activeCount":109},[3640],{"nctId":1267,"briefTitle":1268,"status":102,"phases":3641,"primaryCompletion":1270,"completion":1271,"start":1272,"enrollment":27,"conditions":3642,"interventions":3643},[87],[501,1274,1275],[1277,50,1278],{"trials":3645,"activeCount":109},[],{"trials":3647,"activeCount":109},[],{"trials":3649,"activeCount":109},[],{"trials":3651,"activeCount":109},[],{"intervention":1278,"totalTrials":132,"cells":3653},{"EARLY_PHASE1":3654,"PHASE1":3656,"PHASE2":3662,"PHASE3":3664,"PHASE4":3666,"NA":3668},{"trials":3655,"activeCount":109},[],{"trials":3657,"activeCount":109},[3658],{"nctId":1267,"briefTitle":1268,"status":102,"phases":3659,"primaryCompletion":1270,"completion":1271,"start":1272,"enrollment":27,"conditions":3660,"interventions":3661},[87],[501,1274,1275],[1277,50,1278],{"trials":3663,"activeCount":109},[],{"trials":3665,"activeCount":109},[],{"trials":3667,"activeCount":109},[],{"trials":3669,"activeCount":109},[],{"intervention":3671,"totalTrials":132,"cells":3672},"Cytotoxic T Lymphocytes",{"EARLY_PHASE1":3673,"PHASE1":3675,"PHASE2":3687,"PHASE3":3689,"PHASE4":3691,"NA":3693},{"trials":3674,"activeCount":109},[],{"trials":3676,"activeCount":109},[3677],{"nctId":3678,"briefTitle":3679,"status":102,"phases":3680,"primaryCompletion":3681,"completion":3682,"start":3683,"enrollment":1506,"conditions":3684,"interventions":3686},"NCT04765449","Transfer of Infection Fighting Immune Cells Generated in the Laboratory to High Risk Patients With COVID-19 Infection",[87],"2022-07-29","2023-01-19","2021-09-15",[3685],"Covid19",[3671],{"trials":3688,"activeCount":109},[],{"trials":3690,"activeCount":109},[],{"trials":3692,"activeCount":109},[],{"trials":3694,"activeCount":109},[],{"intervention":2921,"totalTrials":132,"cells":3696},{"EARLY_PHASE1":3697,"PHASE1":3699,"PHASE2":3705,"PHASE3":3707,"PHASE4":3709,"NA":3711},{"trials":3698,"activeCount":109},[],{"trials":3700,"activeCount":109},[3701],{"nctId":2915,"briefTitle":2916,"status":102,"phases":3702,"primaryCompletion":2570,"completion":2570,"start":2918,"enrollment":11,"conditions":3703,"interventions":3704},[87],[2515],[2908,2921],{"trials":3706,"activeCount":109},[],{"trials":3708,"activeCount":109},[],{"trials":3710,"activeCount":109},[],{"trials":3712,"activeCount":109},[],{"intervention":3714,"totalTrials":132,"cells":3715},"Metformin",{"EARLY_PHASE1":3716,"PHASE1":3718,"PHASE2":3732,"PHASE3":3734,"PHASE4":3736,"NA":3738},{"trials":3717,"activeCount":109},[],{"trials":3719,"activeCount":109},[3720],{"nctId":3721,"briefTitle":3722,"status":1775,"phases":3723,"primaryCompletion":3724,"completion":3724,"start":3725,"enrollment":1177,"conditions":3726,"interventions":3731},"NCT05536037","Metformin for the Prevention of Oral Cancer in Patients With Oral Premalignant Lesions",[87],"2024-03-16","2022-05-04",[3727,3728,3729,3730],"Erythroplakia","Leukoplakia","Oral Cavity Carcinoma","Proliferative Verrucous Leukoplakia",[3714],{"trials":3733,"activeCount":109},[],{"trials":3735,"activeCount":109},[],{"trials":3737,"activeCount":109},[],{"trials":3739,"activeCount":109},[],{"intervention":3741,"totalTrials":132,"cells":3742},"Olaparib",{"EARLY_PHASE1":3743,"PHASE1":3745,"PHASE2":3756,"PHASE3":3758,"PHASE4":3760,"NA":3762},{"trials":3744,"activeCount":109},[],{"trials":3746,"activeCount":109},[3747],{"nctId":3748,"briefTitle":3749,"status":1775,"phases":3750,"primaryCompletion":3751,"completion":3751,"start":3752,"enrollment":458,"conditions":3753,"interventions":3755},"NCT03955640","Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences",[87],"2021-08-26","2019-05-20",[3754,557],"Metastatic Malignant Neoplasm in the Chest Wall",[3741],{"trials":3757,"activeCount":109},[],{"trials":3759,"activeCount":109},[],{"trials":3761,"activeCount":109},[],{"trials":3763,"activeCount":109},[],{"intervention":3765,"totalTrials":132,"cells":3766},"Vancomycin",{"EARLY_PHASE1":3767,"PHASE1":3769,"PHASE2":3781,"PHASE3":3783,"PHASE4":3785,"NA":3787},{"trials":3768,"activeCount":109},[],{"trials":3770,"activeCount":109},[3771],{"nctId":3772,"briefTitle":3773,"status":102,"phases":3774,"primaryCompletion":3775,"completion":3776,"start":3777,"enrollment":1177,"conditions":3778,"interventions":3780},"NCT03685747","Vancomycin Pharmacokinetics in Patients on Peritoneal Dialysis",[87],"2020-08-30","2020-10-01","2018-11-15",[3779],"Peritoneal Dialysis-associated Peritonitis",[3765],{"trials":3782,"activeCount":109},[],{"trials":3784,"activeCount":109},[],{"trials":3786,"activeCount":109},[],{"trials":3788,"activeCount":109},[],{"intervention":477,"totalTrials":132,"cells":3790},{"EARLY_PHASE1":3791,"PHASE1":3793,"PHASE2":3799,"PHASE3":3801,"PHASE4":3803,"NA":3805},{"trials":3792,"activeCount":109},[],{"trials":3794,"activeCount":109},[3795],{"nctId":465,"briefTitle":466,"status":102,"phases":3796,"primaryCompletion":468,"completion":469,"start":470,"enrollment":471,"conditions":3797,"interventions":3798},[87],[473,474,475],[477,478,457,479,479],{"trials":3800,"activeCount":109},[],{"trials":3802,"activeCount":109},[],{"trials":3804,"activeCount":109},[],{"trials":3806,"activeCount":109},[],{"intervention":478,"totalTrials":132,"cells":3808},{"EARLY_PHASE1":3809,"PHASE1":3811,"PHASE2":3817,"PHASE3":3819,"PHASE4":3821,"NA":3823},{"trials":3810,"activeCount":109},[],{"trials":3812,"activeCount":109},[3813],{"nctId":465,"briefTitle":466,"status":102,"phases":3814,"primaryCompletion":468,"completion":469,"start":470,"enrollment":471,"conditions":3815,"interventions":3816},[87],[473,474,475],[477,478,457,479,479],{"trials":3818,"activeCount":109},[],{"trials":3820,"activeCount":109},[],{"trials":3822,"activeCount":109},[],{"trials":3824,"activeCount":109},[],{"intervention":3826,"totalTrials":132,"cells":3827},"Hypertonic Saline, Mannitol",{"EARLY_PHASE1":3828,"PHASE1":3830,"PHASE2":3839,"PHASE3":3841,"PHASE4":3843,"NA":3845},{"trials":3829,"activeCount":109},[],{"trials":3831,"activeCount":109},[3832],{"nctId":3833,"briefTitle":3834,"status":151,"phases":3835,"enrollment":126,"conditions":3836,"interventions":3838},"NCT00359697","Comparison of Two Different Medications Used to Treat Elevated Intracranial Pressure",[87],[3837],"Increased Intracranial Pressure",[3826],{"trials":3840,"activeCount":109},[],{"trials":3842,"activeCount":109},[],{"trials":3844,"activeCount":109},[],{"trials":3846,"activeCount":109},[],{"intervention":3848,"totalTrials":132,"cells":3849},"beta hydroxybutyrate (BHB) ester",{"EARLY_PHASE1":3850,"PHASE1":3852,"PHASE2":3863,"PHASE3":3865,"PHASE4":3867,"NA":3869},{"trials":3851,"activeCount":109},[],{"trials":3853,"activeCount":109},[3854],{"nctId":3855,"briefTitle":3856,"status":151,"phases":3857,"primaryCompletion":3858,"completion":3858,"start":3859,"enrollment":2642,"conditions":3860,"interventions":3862},"NCT04370600","Nutritional Ketosis in Heart Failure",[87],"2021-06","2020-06",[3861],"Chronic Heart Failure",[3848],{"trials":3864,"activeCount":109},[],{"trials":3866,"activeCount":109},[],{"trials":3868,"activeCount":109},[],{"trials":3870,"activeCount":109},[],{"intervention":3872,"totalTrials":132,"cells":3873},"Doravirine\u002FLamivudine\u002FTenofovir",{"EARLY_PHASE1":3874,"PHASE1":3876,"PHASE2":3893,"PHASE3":3895,"PHASE4":3897,"NA":3899},{"trials":3875,"activeCount":109},[],{"trials":3877,"activeCount":109},[3878],{"nctId":3879,"briefTitle":3880,"status":102,"phases":3881,"primaryCompletion":3882,"completion":3883,"start":3884,"enrollment":19,"conditions":3885,"interventions":3890},"NCT04283656","Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women",[87],"2022-10-25","2022-12-30","2022-01-04",[3886,3887,3888,3889],"Transgender Health","Gender Dysphoria","Transgender Women","Human Immunodeficiency Virus",[3872,3891,3892],"Spironolactone 100mg","Estradiol 2mg",{"trials":3894,"activeCount":109},[],{"trials":3896,"activeCount":109},[],{"trials":3898,"activeCount":109},[],{"trials":3900,"activeCount":109},[],{"intervention":3891,"totalTrials":132,"cells":3902},{"EARLY_PHASE1":3903,"PHASE1":3905,"PHASE2":3911,"PHASE3":3913,"PHASE4":3915,"NA":3917},{"trials":3904,"activeCount":109},[],{"trials":3906,"activeCount":109},[3907],{"nctId":3879,"briefTitle":3880,"status":102,"phases":3908,"primaryCompletion":3882,"completion":3883,"start":3884,"enrollment":19,"conditions":3909,"interventions":3910},[87],[3886,3887,3888,3889],[3872,3891,3892],{"trials":3912,"activeCount":109},[],{"trials":3914,"activeCount":109},[],{"trials":3916,"activeCount":109},[],{"trials":3918,"activeCount":109},[],{"intervention":3892,"totalTrials":132,"cells":3920},{"EARLY_PHASE1":3921,"PHASE1":3923,"PHASE2":3929,"PHASE3":3931,"PHASE4":3933,"NA":3935},{"trials":3922,"activeCount":109},[],{"trials":3924,"activeCount":109},[3925],{"nctId":3879,"briefTitle":3880,"status":102,"phases":3926,"primaryCompletion":3882,"completion":3883,"start":3884,"enrollment":19,"conditions":3927,"interventions":3928},[87],[3886,3887,3888,3889],[3872,3891,3892],{"trials":3930,"activeCount":109},[],{"trials":3932,"activeCount":109},[],{"trials":3934,"activeCount":109},[],{"trials":3936,"activeCount":109},[],{"intervention":3938,"totalTrials":132,"cells":3939},"Glycopyrrolate",{"EARLY_PHASE1":3940,"PHASE1":3942,"PHASE2":3952,"PHASE3":3954,"PHASE4":3956,"NA":3958},{"trials":3941,"activeCount":109},[],{"trials":3943,"activeCount":109},[3944],{"nctId":3945,"briefTitle":3946,"status":1775,"phases":3947,"primaryCompletion":1777,"completion":1777,"start":3948,"enrollment":30,"conditions":3949,"interventions":3951},"NCT01588717","Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Glycopyrrolate (AIDES-G)",[87],"2012-04",[3950,32],"Hyperhydrosis",[3938],{"trials":3953,"activeCount":109},[],{"trials":3955,"activeCount":109},[],{"trials":3957,"activeCount":109},[],{"trials":3959,"activeCount":109},[],{"intervention":3961,"totalTrials":132,"cells":3962},"vaginal progesterone suppository",{"EARLY_PHASE1":3963,"PHASE1":3965,"PHASE2":3975,"PHASE3":3977,"PHASE4":3979,"NA":3981},{"trials":3964,"activeCount":109},[],{"trials":3966,"activeCount":109},[3967],{"nctId":3968,"briefTitle":3969,"status":102,"phases":3970,"primaryCompletion":2340,"completion":2340,"start":3971,"enrollment":27,"conditions":3972,"interventions":3974},"NCT03340701","Pharmacokinetics of Progesterone in Pregnancy",[87],"2017-11-06",[3973],"Progesterone",[3961],{"trials":3976,"activeCount":109},[],{"trials":3978,"activeCount":109},[],{"trials":3980,"activeCount":109},[],{"trials":3982,"activeCount":109},[],{"intervention":3984,"totalTrials":132,"cells":3985},"micronized Progesterone",{"EARLY_PHASE1":3986,"PHASE1":3988,"PHASE2":3998,"PHASE3":4000,"PHASE4":4002,"NA":4004},{"trials":3987,"activeCount":109},[],{"trials":3989,"activeCount":109},[3990],{"nctId":3991,"briefTitle":3992,"status":1775,"phases":3993,"primaryCompletion":3994,"completion":3994,"start":3995,"enrollment":458,"conditions":3996,"interventions":3997},"NCT04753957","Pharmacokinetics of Progesterone in Pregnancy-2",[87],"2022-02-01","2022-01-07",[171],[3984],{"trials":3999,"activeCount":109},[],{"trials":4001,"activeCount":109},[],{"trials":4003,"activeCount":109},[],{"trials":4005,"activeCount":109},[],{"intervention":4007,"totalTrials":132,"cells":4008},"Perflubutane Microbubble",{"EARLY_PHASE1":4009,"PHASE1":4025,"PHASE2":4027,"PHASE3":4029,"PHASE4":4031,"NA":4033},{"trials":4010,"activeCount":109},[4011],{"nctId":4012,"briefTitle":4013,"status":102,"phases":4014,"primaryCompletion":4015,"completion":4016,"start":4017,"enrollment":4018,"conditions":4019,"interventions":4024},"NCT05105087","Gynecological Sentinel Lymph Nodes CEUS",[86],"2023-11-15","2025-01-29","2022-04-28",9,[4020,4021,4022,4023],"Cervical Carcinoma","Malignant Female Reproductive System Neoplasm","Vaginal Carcinoma","Vulvar Carcinoma",[4007],{"trials":4026,"activeCount":109},[],{"trials":4028,"activeCount":109},[],{"trials":4030,"activeCount":109},[],{"trials":4032,"activeCount":109},[],{"trials":4034,"activeCount":109},[],{"intervention":4036,"totalTrials":132,"cells":4037},"Mirabegron 50 MG",{"EARLY_PHASE1":4038,"PHASE1":4049,"PHASE2":4051,"PHASE3":4053,"PHASE4":4055,"NA":4057},{"trials":4039,"activeCount":109},[4040],{"nctId":4041,"briefTitle":4042,"status":1775,"phases":4043,"primaryCompletion":4044,"completion":4044,"start":4045,"enrollment":30,"conditions":4046,"interventions":4048},"NCT03411252","Mirabegron in Achalasia: A Clinical and Manometric Proof of Concept Pilot Study",[86],"2019-12-15","2018-02-15",[4047],"Achalasia",[4036],{"trials":4050,"activeCount":109},[],{"trials":4052,"activeCount":109},[],{"trials":4054,"activeCount":109},[],{"trials":4056,"activeCount":109},[],{"trials":4058,"activeCount":109},[],{"intervention":4060,"totalTrials":132,"cells":4061},"Rigosertib Sodium",{"EARLY_PHASE1":4062,"PHASE1":4073,"PHASE2":4075,"PHASE3":4077,"PHASE4":4079,"NA":4081},{"trials":4063,"activeCount":109},[4064],{"nctId":4065,"briefTitle":4066,"status":102,"phases":4067,"primaryCompletion":4068,"completion":4068,"start":4069,"enrollment":458,"conditions":4070,"interventions":4072},"NCT04177498","Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC",[86],"2025-05-05","2021-08-24",[4071],"Recessive Dystrophic Epidermolysis Bullosa",[4060],{"trials":4074,"activeCount":109},[],{"trials":4076,"activeCount":109},[],{"trials":4078,"activeCount":109},[],{"trials":4080,"activeCount":109},[],{"trials":4082,"activeCount":109},[],{"intervention":4084,"totalTrials":132,"cells":4085},"Immunoglobulin",{"EARLY_PHASE1":4086,"PHASE1":4096,"PHASE2":4098,"PHASE3":4100,"PHASE4":4102,"NA":4104},{"trials":4087,"activeCount":109},[4088],{"nctId":4089,"briefTitle":4090,"status":1775,"phases":4091,"primaryCompletion":4092,"completion":4092,"start":3587,"enrollment":95,"conditions":4093,"interventions":4095},"NCT02271165","Subcutaneous Immunoglobulin (Hizentra) in Patients With Dermatomyositis: A Proof of Concept Study",[86],"2017-03-02",[4094],"Dermatomyositis",[4084],{"trials":4097,"activeCount":109},[],{"trials":4099,"activeCount":109},[],{"trials":4101,"activeCount":109},[],{"trials":4103,"activeCount":109},[],{"trials":4105,"activeCount":109},[],{"intervention":4107,"totalTrials":132,"cells":4108},"Nicardipine",{"EARLY_PHASE1":4109,"PHASE1":4120,"PHASE2":4122,"PHASE3":4124,"PHASE4":4126,"NA":4128},{"trials":4110,"activeCount":109},[4111],{"nctId":4112,"briefTitle":4113,"status":548,"phases":4114,"primaryCompletion":4115,"completion":4115,"start":4116,"enrollment":109,"conditions":4117,"interventions":4118},"NCT03184155","Prevention of Coronary Microvascular Dysfunction Post-PCI by Intracoronary Nicardipine",[86],"2026-12","2025-12",[2572],[4107,4119],"Sterile Saline",{"trials":4121,"activeCount":109},[],{"trials":4123,"activeCount":109},[],{"trials":4125,"activeCount":109},[],{"trials":4127,"activeCount":109},[],{"trials":4129,"activeCount":109},[],{"intervention":4119,"totalTrials":132,"cells":4131},{"EARLY_PHASE1":4132,"PHASE1":4138,"PHASE2":4140,"PHASE3":4142,"PHASE4":4144,"NA":4146},{"trials":4133,"activeCount":109},[4134],{"nctId":4112,"briefTitle":4113,"status":548,"phases":4135,"primaryCompletion":4115,"completion":4115,"start":4116,"enrollment":109,"conditions":4136,"interventions":4137},[86],[2572],[4107,4119],{"trials":4139,"activeCount":109},[],{"trials":4141,"activeCount":109},[],{"trials":4143,"activeCount":109},[],{"trials":4145,"activeCount":109},[],{"trials":4147,"activeCount":109},[],{"intervention":4149,"totalTrials":132,"cells":4150},"Nitroglycerin ointment",{"EARLY_PHASE1":4151,"PHASE1":4161,"PHASE2":4163,"PHASE3":4165,"PHASE4":4167,"NA":4169},{"trials":4152,"activeCount":109},[4153],{"nctId":4154,"briefTitle":4155,"status":151,"phases":4156,"primaryCompletion":1227,"completion":1227,"start":4157,"enrollment":1480,"conditions":4158,"interventions":4160},"NCT05239013","Safety and Tolerability of Nitro for Radial Artery Dilation",[86],"2022-05-01",[4159],"Artery; Dilatation",[4149],{"trials":4162,"activeCount":109},[],{"trials":4164,"activeCount":109},[],{"trials":4166,"activeCount":109},[],{"trials":4168,"activeCount":109},[],{"trials":4170,"activeCount":109},[],{"intervention":4172,"totalTrials":132,"cells":4173},"Perflutren Lipid Microcpheres",{"EARLY_PHASE1":4174,"PHASE1":4185,"PHASE2":4187,"PHASE3":4189,"PHASE4":4191,"NA":4193},{"trials":4175,"activeCount":109},[4176],{"nctId":4177,"briefTitle":4178,"status":102,"phases":4179,"primaryCompletion":4180,"completion":4180,"start":4181,"enrollment":946,"conditions":4182,"interventions":4184},"NCT04721886","Contrast-Enhanced Ultrasound Scan for the Estimation of Tissue Pressure in Patients With Breast Cancer",[86],"2023-07-11","2020-11-24",[4183],"Breast Carcinoma",[4172],{"trials":4186,"activeCount":109},[],{"trials":4188,"activeCount":109},[],{"trials":4190,"activeCount":109},[],{"trials":4192,"activeCount":109},[],{"trials":4194,"activeCount":109},[],{"intervention":4196,"totalTrials":132,"cells":4197},"Vortioxetine",{"EARLY_PHASE1":4198,"PHASE1":4206,"PHASE2":4208,"PHASE3":4210,"PHASE4":4212,"NA":4214},{"trials":4199,"activeCount":109},[4200],{"nctId":4201,"briefTitle":4202,"status":548,"phases":4203,"primaryCompletion":1777,"completion":1777,"start":2954,"enrollment":109,"conditions":4204,"interventions":4205},"NCT02454426","Vortioxetine in Patients With Major Depressive Disorder and Coronary Artery Disease",[86],[1781,2572],[4196],{"trials":4207,"activeCount":109},[],{"trials":4209,"activeCount":109},[],{"trials":4211,"activeCount":109},[],{"trials":4213,"activeCount":109},[],{"trials":4215,"activeCount":109},[],{"intervention":4217,"totalTrials":132,"cells":4218},"Polyethylene Glycol",{"EARLY_PHASE1":4219,"PHASE1":4236,"PHASE2":4238,"PHASE3":4240,"PHASE4":4242,"NA":4244},{"trials":4220,"activeCount":109},[4221],{"nctId":4222,"briefTitle":4223,"status":151,"phases":4224,"primaryCompletion":4225,"completion":4226,"start":1704,"enrollment":4227,"conditions":4228,"interventions":4233},"NCT03042091","Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery",[86],"2020-10","2021-10",224,[4229,4230,4231,4232],"Colorectal Neoplasms","Diverticulitis","Inflammatory Bowel Diseases","Surgical Site Infection",[4217,4234,4235],"Neomycin","Metronidazole Hydrochloride",{"trials":4237,"activeCount":109},[],{"trials":4239,"activeCount":109},[],{"trials":4241,"activeCount":109},[],{"trials":4243,"activeCount":109},[],{"trials":4245,"activeCount":109},[],{"intervention":4234,"totalTrials":132,"cells":4247},{"EARLY_PHASE1":4248,"PHASE1":4254,"PHASE2":4256,"PHASE3":4258,"PHASE4":4260,"NA":4262},{"trials":4249,"activeCount":109},[4250],{"nctId":4222,"briefTitle":4223,"status":151,"phases":4251,"primaryCompletion":4225,"completion":4226,"start":1704,"enrollment":4227,"conditions":4252,"interventions":4253},[86],[4229,4230,4231,4232],[4217,4234,4235],{"trials":4255,"activeCount":109},[],{"trials":4257,"activeCount":109},[],{"trials":4259,"activeCount":109},[],{"trials":4261,"activeCount":109},[],{"trials":4263,"activeCount":109},[],{"intervention":4235,"totalTrials":132,"cells":4265},{"EARLY_PHASE1":4266,"PHASE1":4272,"PHASE2":4274,"PHASE3":4276,"PHASE4":4278,"NA":4280},{"trials":4267,"activeCount":109},[4268],{"nctId":4222,"briefTitle":4223,"status":151,"phases":4269,"primaryCompletion":4225,"completion":4226,"start":1704,"enrollment":4227,"conditions":4270,"interventions":4271},[86],[4229,4230,4231,4232],[4217,4234,4235],{"trials":4273,"activeCount":109},[],{"trials":4275,"activeCount":109},[],{"trials":4277,"activeCount":109},[],{"trials":4279,"activeCount":109},[],{"trials":4281,"activeCount":109},[],{"intervention":4283,"totalTrials":458,"cells":4284},"Ferric carboxymaltose",{"EARLY_PHASE1":4285,"PHASE1":4287,"PHASE2":4289,"PHASE3":4291,"PHASE4":4293,"NA":4309},{"trials":4286,"activeCount":109},[],{"trials":4288,"activeCount":109},[],{"trials":4290,"activeCount":109},[],{"trials":4292,"activeCount":109},[],{"trials":4294,"activeCount":109},[4295],{"nctId":4296,"briefTitle":4297,"status":102,"phases":4298,"primaryCompletion":4299,"completion":4300,"start":4301,"enrollment":4302,"conditions":4303,"interventions":4306},"NCT05358509","Reducing Anemia in Pregnancy in India: the RAPIDIRON Trial",[90],"2023-12-14","2024-01-21","2021-03-15",4368,[4304,4305,172],"Iron Deficiency Anemia","Infant, Low Birth Weight",[4283,4307,4308],"Iron isomaltoside","Ferric Sulfate",{"trials":4310,"activeCount":109},[4311,4326],{"nctId":4312,"briefTitle":4313,"status":102,"phases":4314,"primaryCompletion":4315,"completion":4316,"start":4317,"enrollment":4318,"conditions":4319,"interventions":4325},"NCT05545527","Neuroimaging Ancillary Study",[],"2024-02-14","2025-04-07","2023-02-21",184,[4304,4320,4321,4322,4323,4324],"Iron Deficiency Anemia of Pregnancy","Neurodevelopmental Disorder of Foetus","Iron Deficiency Anemia Treatment","Fetal Neurodevelopmental Disorder","Child Development",[4283,4307,4308],{"nctId":4327,"briefTitle":4328,"status":151,"phases":4329,"primaryCompletion":153,"completion":4330,"start":4331,"enrollment":4332,"conditions":4333,"interventions":4336},"NCT05504863","RAPIDIRON Trial Follow-up Study: RAPIDIRON-KIDS Study",[],"2026-01","2022-10-11",538,[4304,4334,4335],"Neurodevelopmental Abnormality","Autism Spectrum Disorder",[4283,4307,4308],{"intervention":4307,"totalTrials":458,"cells":4338},{"EARLY_PHASE1":4339,"PHASE1":4341,"PHASE2":4343,"PHASE3":4345,"PHASE4":4347,"NA":4353},{"trials":4340,"activeCount":109},[],{"trials":4342,"activeCount":109},[],{"trials":4344,"activeCount":109},[],{"trials":4346,"activeCount":109},[],{"trials":4348,"activeCount":109},[4349],{"nctId":4296,"briefTitle":4297,"status":102,"phases":4350,"primaryCompletion":4299,"completion":4300,"start":4301,"enrollment":4302,"conditions":4351,"interventions":4352},[90],[4304,4305,172],[4283,4307,4308],{"trials":4354,"activeCount":109},[4355,4359],{"nctId":4312,"briefTitle":4313,"status":102,"phases":4356,"primaryCompletion":4315,"completion":4316,"start":4317,"enrollment":4318,"conditions":4357,"interventions":4358},[],[4304,4320,4321,4322,4323,4324],[4283,4307,4308],{"nctId":4327,"briefTitle":4328,"status":151,"phases":4360,"primaryCompletion":153,"completion":4330,"start":4331,"enrollment":4332,"conditions":4361,"interventions":4362},[],[4304,4334,4335],[4283,4307,4308],{"intervention":4308,"totalTrials":458,"cells":4364},{"EARLY_PHASE1":4365,"PHASE1":4367,"PHASE2":4369,"PHASE3":4371,"PHASE4":4373,"NA":4379},{"trials":4366,"activeCount":109},[],{"trials":4368,"activeCount":109},[],{"trials":4370,"activeCount":109},[],{"trials":4372,"activeCount":109},[],{"trials":4374,"activeCount":109},[4375],{"nctId":4296,"briefTitle":4297,"status":102,"phases":4376,"primaryCompletion":4299,"completion":4300,"start":4301,"enrollment":4302,"conditions":4377,"interventions":4378},[90],[4304,4305,172],[4283,4307,4308],{"trials":4380,"activeCount":109},[4381,4385],{"nctId":4312,"briefTitle":4313,"status":102,"phases":4382,"primaryCompletion":4315,"completion":4316,"start":4317,"enrollment":4318,"conditions":4383,"interventions":4384},[],[4304,4320,4321,4322,4323,4324],[4283,4307,4308],{"nctId":4327,"briefTitle":4328,"status":151,"phases":4386,"primaryCompletion":153,"completion":4330,"start":4331,"enrollment":4332,"conditions":4387,"interventions":4388},[],[4304,4334,4335],[4283,4307,4308],{"intervention":2048,"totalTrials":95,"cells":4390},{"EARLY_PHASE1":4391,"PHASE1":4393,"PHASE2":4395,"PHASE3":4397,"PHASE4":4399,"NA":4405},{"trials":4392,"activeCount":109},[],{"trials":4394,"activeCount":109},[],{"trials":4396,"activeCount":109},[],{"trials":4398,"activeCount":109},[],{"trials":4400,"activeCount":109},[4401],{"nctId":2040,"briefTitle":2041,"status":548,"phases":4402,"primaryCompletion":2043,"completion":2044,"start":2045,"enrollment":109,"conditions":4403,"interventions":4404},[90],[1979,1980],[2048,2027],{"trials":4406,"activeCount":109},[4407],{"nctId":4408,"briefTitle":4409,"status":102,"phases":4410,"primaryCompletion":4411,"completion":4411,"start":4412,"enrollment":1480,"conditions":4413,"interventions":4416},"NCT04807504","Ropivacaine Pharmacokinetics in ESP Blocks",[],"2021-09-23","2021-03-26",[4414,23,4415],"Local Anesthetic Systemic Toxicity","Quality of Recovery",[4417],"Ropivacaine",{"intervention":4419,"totalTrials":95,"cells":4420},"terazosin",{"EARLY_PHASE1":4421,"PHASE1":4423,"PHASE2":4425,"PHASE3":4427,"PHASE4":4429,"NA":4441},{"trials":4422,"activeCount":109},[],{"trials":4424,"activeCount":109},[],{"trials":4426,"activeCount":109},[],{"trials":4428,"activeCount":109},[],{"trials":4430,"activeCount":109},[4431],{"nctId":4432,"briefTitle":4433,"status":102,"phases":4434,"primaryCompletion":4435,"completion":4435,"start":4436,"enrollment":4437,"conditions":4438,"interventions":4440},"NCT00449683","Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin",[90],"2013-08","2007-03",23,[4439],"Hyperhidrosis",[4419],{"trials":4442,"activeCount":109},[4443],{"nctId":4444,"briefTitle":4445,"status":102,"phases":4446,"primaryCompletion":4447,"completion":4448,"start":4449,"enrollment":1230,"conditions":4450,"interventions":4452},"NCT00237510","Pilot Study of Terazosin in Treatment of Antidepressant Induced Excessive Sweating",[91],"2006-05","2007-05","2005-05",[4451],"Antidepressant Induced Excessive Sweating",[4419],{"intervention":4454,"totalTrials":95,"cells":4455},"levetiracetam",{"EARLY_PHASE1":4456,"PHASE1":4458,"PHASE2":4460,"PHASE3":4462,"PHASE4":4464,"NA":4466},{"trials":4457,"activeCount":109},[],{"trials":4459,"activeCount":109},[],{"trials":4461,"activeCount":109},[],{"trials":4463,"activeCount":109},[],{"trials":4465,"activeCount":109},[],{"trials":4467,"activeCount":109},[4468,4477],{"nctId":4469,"briefTitle":4470,"status":102,"phases":4471,"primaryCompletion":4472,"completion":2021,"start":4473,"enrollment":4474,"conditions":4475,"interventions":4476},"NCT00203216","A Clinical Study Examining the Safety and Effectiveness of a New Medication (Keppra®) for the Prevention of Migraine Headaches",[91],"2005-01","2002-09",31,[15],[4454],{"nctId":4478,"briefTitle":4479,"status":1775,"phases":4480,"primaryCompletion":2596,"completion":2596,"start":2195,"enrollment":3112,"conditions":4481,"interventions":4482},"NCT00774306","Antiepileptic Drugs and Vascular Risk Markers",[91],[3186],[4483,4484,4454],"phenytoin","valproate",{"intervention":4486,"totalTrials":132,"cells":4487},"Genetic Testing",{"EARLY_PHASE1":4488,"PHASE1":4490,"PHASE2":4492,"PHASE3":4494,"PHASE4":4496,"NA":4498},{"trials":4489,"activeCount":109},[],{"trials":4491,"activeCount":109},[],{"trials":4493,"activeCount":109},[],{"trials":4495,"activeCount":109},[],{"trials":4497,"activeCount":109},[],{"trials":4499,"activeCount":109},[4500],{"nctId":4501,"briefTitle":4502,"status":102,"phases":4503,"primaryCompletion":4504,"completion":4505,"start":4506,"enrollment":4507,"conditions":4508,"interventions":4512},"NCT04447703","Technology-Enhanced Acceleration of Germline Evaluation for Therapy, TARGET Study",[91],"2022-08-09","2024-09-10","2020-08-27",346,[4509,4510,3472,3473,4511],"Biochemically Recurrent Prostate Carcinoma","Metastatic Prostate Carcinoma","Stage IV Prostate Cancer AJCC v8",[4486,4486],{"intervention":4514,"totalTrials":132,"cells":4515},"Tranexamic Acid",{"EARLY_PHASE1":4516,"PHASE1":4518,"PHASE2":4520,"PHASE3":4522,"PHASE4":4524,"NA":4526},{"trials":4517,"activeCount":109},[],{"trials":4519,"activeCount":109},[],{"trials":4521,"activeCount":109},[],{"trials":4523,"activeCount":109},[],{"trials":4525,"activeCount":109},[],{"trials":4527,"activeCount":109},[4528],{"nctId":4529,"briefTitle":4530,"status":102,"phases":4531,"primaryCompletion":4532,"completion":4532,"start":3752,"enrollment":126,"conditions":4533,"interventions":4538},"NCT03897621","The Effect of Tranexamic Acid on Blood Coagulation in Total Hip Arthroplasty Surgery",[91],"2022-12-20",[4534,4535,4536,4514,4537],"Coagulation; Intravascular","Rotational Thromboelastometry","Fibrinolysis; Hemorrhage","Total Hip Arthroplasty",[4514],{"intervention":4540,"totalTrials":132,"cells":4541},"STOPAIN topical gel",{"EARLY_PHASE1":4542,"PHASE1":4544,"PHASE2":4546,"PHASE3":4548,"PHASE4":4550,"NA":4552},{"trials":4543,"activeCount":109},[],{"trials":4545,"activeCount":109},[],{"trials":4547,"activeCount":109},[],{"trials":4549,"activeCount":109},[],{"trials":4551,"activeCount":109},[],{"trials":4553,"activeCount":109},[4554],{"nctId":4555,"briefTitle":4556,"status":102,"phases":4557,"primaryCompletion":4558,"completion":4558,"start":4559,"enrollment":4560,"conditions":4561,"interventions":4563},"NCT01687101","STOPAIN in the Treatment of a Single Migraine Attack",[91],"2013-05","2012-05",32,[15,4562],"Headache",[4540],{"intervention":4565,"totalTrials":132,"cells":4566},"Amniotic suspension allograft",{"EARLY_PHASE1":4567,"PHASE1":4569,"PHASE2":4571,"PHASE3":4573,"PHASE4":4575,"NA":4577},{"trials":4568,"activeCount":109},[],{"trials":4570,"activeCount":109},[],{"trials":4572,"activeCount":109},[],{"trials":4574,"activeCount":109},[],{"trials":4576,"activeCount":109},[],{"trials":4578,"activeCount":109},[4579],{"nctId":4580,"briefTitle":4581,"status":151,"phases":4582,"primaryCompletion":4583,"completion":4584,"start":4585,"enrollment":126,"conditions":4586,"interventions":4588},"NCT06425575","Resolution of Pudendal Neuralgia in Chronic Pelvic Pain Using a Novel Biologic Therapy",[],"2023-10-31","2024-07-01","2019-04-01",[4587],"Chronic Pelvic Pain Syndrome",[4565],{"intervention":4590,"totalTrials":132,"cells":4591},"Genocept Assay",{"EARLY_PHASE1":4592,"PHASE1":4594,"PHASE2":4596,"PHASE3":4598,"PHASE4":4600,"NA":4602},{"trials":4593,"activeCount":109},[],{"trials":4595,"activeCount":109},[],{"trials":4597,"activeCount":109},[],{"trials":4599,"activeCount":109},[],{"trials":4601,"activeCount":109},[],{"trials":4603,"activeCount":109},[4604],{"nctId":4605,"briefTitle":4606,"status":102,"phases":4607,"primaryCompletion":2896,"completion":3058,"start":4608,"enrollment":4609,"conditions":4610,"interventions":4612},"NCT02883660","Genecept Assay and Adverse Effects of Antidepressants",[],"2013-02",74,[32,4611],"Adverse Effects",[4590],{"intervention":4614,"totalTrials":132,"cells":4615},"simethicone",{"EARLY_PHASE1":4616,"PHASE1":4618,"PHASE2":4620,"PHASE3":4622,"PHASE4":4624,"NA":4626},{"trials":4617,"activeCount":109},[],{"trials":4619,"activeCount":109},[],{"trials":4621,"activeCount":109},[],{"trials":4623,"activeCount":109},[],{"trials":4625,"activeCount":109},[],{"trials":4627,"activeCount":109},[4628],{"nctId":4629,"briefTitle":4630,"status":102,"phases":4631,"primaryCompletion":2512,"completion":2641,"start":4632,"enrollment":4633,"conditions":4634,"interventions":4636},"NCT01209806","The Effects of Moviprep With Simethicone on Colonic Bubbles",[91],"2009-11",140,[4635],"Bubbles in Colon at Time of Colonoscopy",[4614],{"intervention":4638,"totalTrials":132,"cells":4639},"Soy Isoflavones",{"EARLY_PHASE1":4640,"PHASE1":4642,"PHASE2":4644,"PHASE3":4646,"PHASE4":4648,"NA":4650},{"trials":4641,"activeCount":109},[],{"trials":4643,"activeCount":109},[],{"trials":4645,"activeCount":109},[],{"trials":4647,"activeCount":109},[],{"trials":4649,"activeCount":109},[],{"trials":4651,"activeCount":109},[4652],{"nctId":4653,"briefTitle":4654,"status":102,"phases":4655,"completion":4656,"start":4657,"enrollment":946,"conditions":4658,"interventions":4660},"NCT00203255","Clinical Study Examining Use of an Over-the-Counter Supplement for the Prevention of Menstrually-Associated Migraine Headache",[91],"2005-03","2003-05",[4659],"Migraine Headache",[4638],{"intervention":4662,"totalTrials":132,"cells":4663},"dihydroergotamine mesylate",{"EARLY_PHASE1":4664,"PHASE1":4666,"PHASE2":4668,"PHASE3":4670,"PHASE4":4672,"NA":4674},{"trials":4665,"activeCount":109},[],{"trials":4667,"activeCount":109},[],{"trials":4669,"activeCount":109},[],{"trials":4671,"activeCount":109},[],{"trials":4673,"activeCount":109},[],{"trials":4675,"activeCount":109},[4676],{"nctId":4677,"briefTitle":4678,"status":102,"phases":4679,"primaryCompletion":4656,"completion":4656,"start":2264,"enrollment":3340,"conditions":4680,"interventions":4681},"NCT00203268","A Study Examining the Use of a Migraine Medicine in the Treatment of Two Migraine Attacks in Patients Who Have Increased Skin Sensitivity",[91],[15],[4662],{"intervention":4683,"totalTrials":132,"cells":4684},"oral acetaminophen",{"EARLY_PHASE1":4685,"PHASE1":4687,"PHASE2":4689,"PHASE3":4691,"PHASE4":4693,"NA":4695},{"trials":4686,"activeCount":109},[],{"trials":4688,"activeCount":109},[],{"trials":4690,"activeCount":109},[],{"trials":4692,"activeCount":109},[],{"trials":4694,"activeCount":109},[],{"trials":4696,"activeCount":109},[4697],{"nctId":4698,"briefTitle":4699,"status":151,"phases":4700,"primaryCompletion":4701,"start":4435,"enrollment":585,"conditions":4702,"interventions":4703},"NCT02067442","Prospective, Randomized, Double Blind Study Comparing IV vs PO Acetaminophen in Patients Undergoing Lumbar Discectomy",[91],"2015-07",[23],[4683,4704],"intravenous acetaminophen",{"intervention":4704,"totalTrials":132,"cells":4706},{"EARLY_PHASE1":4707,"PHASE1":4709,"PHASE2":4711,"PHASE3":4713,"PHASE4":4715,"NA":4717},{"trials":4708,"activeCount":109},[],{"trials":4710,"activeCount":109},[],{"trials":4712,"activeCount":109},[],{"trials":4714,"activeCount":109},[],{"trials":4716,"activeCount":109},[],{"trials":4718,"activeCount":109},[4719],{"nctId":4698,"briefTitle":4699,"status":151,"phases":4720,"primaryCompletion":4701,"start":4435,"enrollment":585,"conditions":4721,"interventions":4722},[91],[23],[4683,4704],{"intervention":4724,"totalTrials":132,"cells":4725},"HyQvia",{"EARLY_PHASE1":4726,"PHASE1":4728,"PHASE2":4730,"PHASE3":4732,"PHASE4":4734,"NA":4736},{"trials":4727,"activeCount":109},[],{"trials":4729,"activeCount":109},[],{"trials":4731,"activeCount":109},[],{"trials":4733,"activeCount":109},[],{"trials":4735,"activeCount":109},[],{"trials":4737,"activeCount":109},[4738],{"nctId":4739,"briefTitle":4740,"status":151,"phases":4741,"primaryCompletion":4742,"completion":2798,"start":4743,"enrollment":9,"conditions":4744,"interventions":4746},"NCT03829826","Efficacy and Mechanism of Action of SCIg in Patients With Stiff Person Syndrome (SPS)",[],"2020-02","2019-06",[4745],"Stiff-Person Syndrome",[4724],{"intervention":4748,"totalTrials":132,"cells":4749},"Alteplase",{"EARLY_PHASE1":4750,"PHASE1":4752,"PHASE2":4754,"PHASE3":4756,"PHASE4":4758,"NA":4760},{"trials":4751,"activeCount":109},[],{"trials":4753,"activeCount":109},[],{"trials":4755,"activeCount":109},[],{"trials":4757,"activeCount":109},[],{"trials":4759,"activeCount":109},[],{"trials":4761,"activeCount":109},[4762],{"nctId":4763,"briefTitle":4764,"status":151,"phases":4765,"primaryCompletion":4766,"start":2778,"enrollment":353,"conditions":4767,"interventions":4769},"NCT02447094","Quality of Life After Stroke Using a Telemedicine-based Stroke Network",[],"2017-02",[4768],"Stroke",[4748],{"intervention":4771,"totalTrials":132,"cells":4772},"Frovatriptan",{"EARLY_PHASE1":4773,"PHASE1":4775,"PHASE2":4777,"PHASE3":4779,"PHASE4":4781,"NA":4783},{"trials":4774,"activeCount":109},[],{"trials":4776,"activeCount":109},[],{"trials":4778,"activeCount":109},[],{"trials":4780,"activeCount":109},[],{"trials":4782,"activeCount":109},[],{"trials":4784,"activeCount":109},[4785],{"nctId":4786,"briefTitle":4787,"status":102,"phases":4788,"primaryCompletion":2979,"completion":4789,"start":4790,"enrollment":4609,"conditions":4791,"interventions":4792},"NCT00440232","A Research Study To Evaluate If Frovatriptan Is Safe And Effective In Preventing Migraine Headache After Fasting",[91],"2009-09","2007-07",[15],[4771],{"intervention":4794,"totalTrials":132,"cells":4795},"Nicotine Replacement",{"EARLY_PHASE1":4796,"PHASE1":4798,"PHASE2":4800,"PHASE3":4802,"PHASE4":4804,"NA":4806},{"trials":4797,"activeCount":109},[],{"trials":4799,"activeCount":109},[],{"trials":4801,"activeCount":109},[],{"trials":4803,"activeCount":109},[],{"trials":4805,"activeCount":109},[],{"trials":4807,"activeCount":109},[4808],{"nctId":4809,"briefTitle":4810,"status":102,"phases":4811,"primaryCompletion":4812,"completion":4812,"start":4813,"enrollment":340,"conditions":4814,"interventions":4817},"NCT04694846","Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use",[91],"2024-08-16","2020-08-19",[4815,4816],"Lung Non-Small Cell Carcinoma","Head and Neck Squamous Cell Carcinoma",[4794,4818,4819],"Bupropion Hydrochloride Controlled-release","Varenicline",{"intervention":4818,"totalTrials":132,"cells":4821},{"EARLY_PHASE1":4822,"PHASE1":4824,"PHASE2":4826,"PHASE3":4828,"PHASE4":4830,"NA":4832},{"trials":4823,"activeCount":109},[],{"trials":4825,"activeCount":109},[],{"trials":4827,"activeCount":109},[],{"trials":4829,"activeCount":109},[],{"trials":4831,"activeCount":109},[],{"trials":4833,"activeCount":109},[4834],{"nctId":4809,"briefTitle":4810,"status":102,"phases":4835,"primaryCompletion":4812,"completion":4812,"start":4813,"enrollment":340,"conditions":4836,"interventions":4837},[91],[4815,4816],[4794,4818,4819],{"intervention":4819,"totalTrials":132,"cells":4839},{"EARLY_PHASE1":4840,"PHASE1":4842,"PHASE2":4844,"PHASE3":4846,"PHASE4":4848,"NA":4850},{"trials":4841,"activeCount":109},[],{"trials":4843,"activeCount":109},[],{"trials":4845,"activeCount":109},[],{"trials":4847,"activeCount":109},[],{"trials":4849,"activeCount":109},[],{"trials":4851,"activeCount":109},[4852],{"nctId":4809,"briefTitle":4810,"status":102,"phases":4853,"primaryCompletion":4812,"completion":4812,"start":4813,"enrollment":340,"conditions":4854,"interventions":4855},[91],[4815,4816],[4794,4818,4819],{"intervention":4857,"totalTrials":132,"cells":4858},"Oxytocin",{"EARLY_PHASE1":4859,"PHASE1":4861,"PHASE2":4863,"PHASE3":4865,"PHASE4":4867,"NA":4869},{"trials":4860,"activeCount":109},[],{"trials":4862,"activeCount":109},[],{"trials":4864,"activeCount":109},[],{"trials":4866,"activeCount":109},[],{"trials":4868,"activeCount":109},[],{"trials":4870,"activeCount":109},[4871],{"nctId":4872,"briefTitle":4873,"status":102,"phases":4874,"primaryCompletion":4875,"completion":4875,"start":4876,"enrollment":4877,"conditions":4878,"interventions":4882},"NCT04492072","Misoprostol With Mechanical Dilation Versus Oxytocin With Mechanical Dilation for High-risk Pregnancy Inductions",[91],"2022-05-26","2020-08-17",150,[4879,4880,4857,4881],"Cesarean Section","Misoprostol","High Risk Pregnancy",[4857,4880],{"intervention":4880,"totalTrials":132,"cells":4884},{"EARLY_PHASE1":4885,"PHASE1":4887,"PHASE2":4889,"PHASE3":4891,"PHASE4":4893,"NA":4895},{"trials":4886,"activeCount":109},[],{"trials":4888,"activeCount":109},[],{"trials":4890,"activeCount":109},[],{"trials":4892,"activeCount":109},[],{"trials":4894,"activeCount":109},[],{"trials":4896,"activeCount":109},[4897],{"nctId":4872,"briefTitle":4873,"status":102,"phases":4898,"primaryCompletion":4875,"completion":4875,"start":4876,"enrollment":4877,"conditions":4899,"interventions":4900},[91],[4879,4880,4857,4881],[4857,4880],{"intervention":4902,"totalTrials":132,"cells":4903},"Olanzapine during first intervention period and placebo during second intervention period",{"EARLY_PHASE1":4904,"PHASE1":4906,"PHASE2":4908,"PHASE3":4910,"PHASE4":4912,"NA":4914},{"trials":4905,"activeCount":109},[],{"trials":4907,"activeCount":109},[],{"trials":4909,"activeCount":109},[],{"trials":4911,"activeCount":109},[],{"trials":4913,"activeCount":109},[],{"trials":4915,"activeCount":109},[4916],{"nctId":4917,"briefTitle":4918,"status":1775,"phases":4919,"primaryCompletion":4920,"completion":2116,"start":4921,"enrollment":458,"conditions":4922,"interventions":4923},"NCT00203307","A Research Study Examining the Use of Olanzapine for the Prevention of Migraine",[91],"2006-03","2004-05",[15],[4902],{"intervention":4925,"totalTrials":132,"cells":4926},"Amnion Tendon Wrapping",{"EARLY_PHASE1":4927,"PHASE1":4929,"PHASE2":4931,"PHASE3":4933,"PHASE4":4935,"NA":4937},{"trials":4928,"activeCount":109},[],{"trials":4930,"activeCount":109},[],{"trials":4932,"activeCount":109},[],{"trials":4934,"activeCount":109},[],{"trials":4936,"activeCount":109},[],{"trials":4938,"activeCount":109},[4939],{"nctId":4940,"briefTitle":4941,"status":151,"phases":4942,"primaryCompletion":4943,"start":3183,"enrollment":523,"conditions":4944,"interventions":4949},"NCT03013582","Amniotic Membrane Wrapping and Tenolysis Versus Tenolysis Alone for Treatment of Tendon Adhesions of the Hand\u002FWrist",[91],"2018-07",[4945,4946,4947,4948],"Tendinopathy","Adhesions Nos Postoperative","Scar","Fibrosis",[4925],{"intervention":4951,"totalTrials":132,"cells":4952},"0.5% bupivicaine and 2% lidocaine",{"EARLY_PHASE1":4953,"PHASE1":4955,"PHASE2":4957,"PHASE3":4959,"PHASE4":4961,"NA":4963},{"trials":4954,"activeCount":109},[],{"trials":4956,"activeCount":109},[],{"trials":4958,"activeCount":109},[],{"trials":4960,"activeCount":109},[],{"trials":4962,"activeCount":109},[],{"trials":4964,"activeCount":109},[4965],{"nctId":4966,"briefTitle":4967,"status":1775,"phases":4968,"primaryCompletion":4969,"completion":4969,"start":4920,"enrollment":95,"conditions":4970,"interventions":4971},"NCT00329732","Research Study of Greater Occipital Nerve Block As A Treatment For Prolonged Migraine Attacks",[91],"2006-04",[15],[4951,4972],"Saline placebo",{"intervention":4972,"totalTrials":132,"cells":4974},{"EARLY_PHASE1":4975,"PHASE1":4977,"PHASE2":4979,"PHASE3":4981,"PHASE4":4983,"NA":4985},{"trials":4976,"activeCount":109},[],{"trials":4978,"activeCount":109},[],{"trials":4980,"activeCount":109},[],{"trials":4982,"activeCount":109},[],{"trials":4984,"activeCount":109},[],{"trials":4986,"activeCount":109},[4987],{"nctId":4966,"briefTitle":4967,"status":1775,"phases":4988,"primaryCompletion":4969,"completion":4969,"start":4920,"enrollment":95,"conditions":4989,"interventions":4990},[91],[15],[4951,4972],{"intervention":4992,"totalTrials":132,"cells":4993},"Bivalent COVID-19 Booster",{"EARLY_PHASE1":4994,"PHASE1":4996,"PHASE2":4998,"PHASE3":5000,"PHASE4":5002,"NA":5004},{"trials":4995,"activeCount":109},[],{"trials":4997,"activeCount":109},[],{"trials":4999,"activeCount":109},[],{"trials":5001,"activeCount":109},[],{"trials":5003,"activeCount":109},[],{"trials":5005,"activeCount":109},[5006],{"nctId":5007,"briefTitle":5008,"status":102,"phases":5009,"primaryCompletion":5010,"completion":5010,"start":5011,"enrollment":4877,"conditions":5012,"interventions":5013},"NCT05543993","COVID Booster in Pregnancy and Lactation",[],"2024-06-10","2022-09-29",[2801],[4992],{"intervention":5015,"totalTrials":132,"cells":5016},"PEG-SD",{"EARLY_PHASE1":5017,"PHASE1":5019,"PHASE2":5021,"PHASE3":5023,"PHASE4":5025,"NA":5027},{"trials":5018,"activeCount":109},[],{"trials":5020,"activeCount":109},[],{"trials":5022,"activeCount":109},[],{"trials":5024,"activeCount":109},[],{"trials":5026,"activeCount":109},[],{"trials":5028,"activeCount":109},[5029],{"nctId":5030,"briefTitle":5031,"status":102,"phases":5032,"primaryCompletion":4559,"completion":2641,"start":3566,"enrollment":5033,"conditions":5034,"interventions":5035},"NCT01299779","Incidence of Hyponatremia in PEG-SD Compared to PEG-ELS",[91],460,[3188],[5015,5036],"PEG-ELS",{"intervention":5036,"totalTrials":132,"cells":5038},{"EARLY_PHASE1":5039,"PHASE1":5041,"PHASE2":5043,"PHASE3":5045,"PHASE4":5047,"NA":5049},{"trials":5040,"activeCount":109},[],{"trials":5042,"activeCount":109},[],{"trials":5044,"activeCount":109},[],{"trials":5046,"activeCount":109},[],{"trials":5048,"activeCount":109},[],{"trials":5050,"activeCount":109},[5051],{"nctId":5030,"briefTitle":5031,"status":102,"phases":5052,"primaryCompletion":4559,"completion":2641,"start":3566,"enrollment":5033,"conditions":5053,"interventions":5054},[91],[3188],[5015,5036],{"intervention":5056,"totalTrials":132,"cells":5057},"lidocaine, bupivicaine and saline",{"EARLY_PHASE1":5058,"PHASE1":5060,"PHASE2":5062,"PHASE3":5064,"PHASE4":5066,"NA":5068},{"trials":5059,"activeCount":109},[],{"trials":5061,"activeCount":109},[],{"trials":5063,"activeCount":109},[],{"trials":5065,"activeCount":109},[],{"trials":5067,"activeCount":109},[],{"trials":5069,"activeCount":109},[5070],{"nctId":5071,"briefTitle":5072,"status":102,"phases":5073,"primaryCompletion":2116,"completion":2116,"start":5074,"enrollment":1098,"conditions":5075,"interventions":5076},"NCT00203294","A Research Study to Examine the Difference Between Local Anesthetics Alone and Local Anesthetics Plus Steroids in the Treatment of Chronic Headache",[91],"2005-06",[15],[5056,5077],"lidocaine plus bupivicaine plus triamcinolone",{"intervention":5077,"totalTrials":132,"cells":5079},{"EARLY_PHASE1":5080,"PHASE1":5082,"PHASE2":5084,"PHASE3":5086,"PHASE4":5088,"NA":5090},{"trials":5081,"activeCount":109},[],{"trials":5083,"activeCount":109},[],{"trials":5085,"activeCount":109},[],{"trials":5087,"activeCount":109},[],{"trials":5089,"activeCount":109},[],{"trials":5091,"activeCount":109},[5092],{"nctId":5071,"briefTitle":5072,"status":102,"phases":5093,"primaryCompletion":2116,"completion":2116,"start":5074,"enrollment":1098,"conditions":5094,"interventions":5095},[91],[15],[5056,5077],{"intervention":5097,"totalTrials":132,"cells":5098},"Aspirin 81 mg",{"EARLY_PHASE1":5099,"PHASE1":5101,"PHASE2":5103,"PHASE3":5105,"PHASE4":5107,"NA":5109},{"trials":5100,"activeCount":109},[],{"trials":5102,"activeCount":109},[],{"trials":5104,"activeCount":109},[],{"trials":5106,"activeCount":109},[],{"trials":5108,"activeCount":109},[],{"trials":5110,"activeCount":109},[5111],{"nctId":5112,"briefTitle":5113,"status":102,"phases":5114,"primaryCompletion":5115,"completion":5116,"start":5117,"enrollment":5118,"conditions":5119,"interventions":5120},"NCT04295850","Antenatal Platelet Response On Aspirin and Correlation With HDP (Hypertensive Disorders of Pregnancy)",[],"2022-11-18","2023-06-30","2020-08-21",130,[862],[5097],{"intervention":5122,"totalTrials":132,"cells":5123},"COVID-19 vaccine",{"EARLY_PHASE1":5124,"PHASE1":5126,"PHASE2":5128,"PHASE3":5130,"PHASE4":5132,"NA":5134},{"trials":5125,"activeCount":109},[],{"trials":5127,"activeCount":109},[],{"trials":5129,"activeCount":109},[],{"trials":5131,"activeCount":109},[],{"trials":5133,"activeCount":109},[],{"trials":5135,"activeCount":109},[5136],{"nctId":5137,"briefTitle":5138,"status":102,"phases":5139,"primaryCompletion":5140,"completion":5140,"start":5141,"enrollment":5142,"conditions":5143,"interventions":5144},"NCT04659759","COVID-19 Pregnancy Related Immunological, Clinical and Epidemiological Factors and Perinatal Outcomes",[],"2025-08-30","2020-11-17",105,[3685],[5122],{"intervention":4483,"totalTrials":132,"cells":5146},{"EARLY_PHASE1":5147,"PHASE1":5149,"PHASE2":5151,"PHASE3":5153,"PHASE4":5155,"NA":5157},{"trials":5148,"activeCount":109},[],{"trials":5150,"activeCount":109},[],{"trials":5152,"activeCount":109},[],{"trials":5154,"activeCount":109},[],{"trials":5156,"activeCount":109},[],{"trials":5158,"activeCount":109},[5159],{"nctId":4478,"briefTitle":4479,"status":1775,"phases":5160,"primaryCompletion":2596,"completion":2596,"start":2195,"enrollment":3112,"conditions":5161,"interventions":5162},[91],[3186],[4483,4484,4454],{"intervention":4484,"totalTrials":132,"cells":5164},{"EARLY_PHASE1":5165,"PHASE1":5167,"PHASE2":5169,"PHASE3":5171,"PHASE4":5173,"NA":5175},{"trials":5166,"activeCount":109},[],{"trials":5168,"activeCount":109},[],{"trials":5170,"activeCount":109},[],{"trials":5172,"activeCount":109},[],{"trials":5174,"activeCount":109},[],{"trials":5176,"activeCount":109},[5177],{"nctId":4478,"briefTitle":4479,"status":1775,"phases":5178,"primaryCompletion":2596,"completion":2596,"start":2195,"enrollment":3112,"conditions":5179,"interventions":5180},[91],[3186],[4483,4484,4454],{"intervention":5182,"totalTrials":132,"cells":5183},"bictegravir\u002Femtricitabine\u002Ftenofovir alafenamide",{"EARLY_PHASE1":5184,"PHASE1":5186,"PHASE2":5188,"PHASE3":5190,"PHASE4":5192,"NA":5194},{"trials":5185,"activeCount":109},[],{"trials":5187,"activeCount":109},[],{"trials":5189,"activeCount":109},[],{"trials":5191,"activeCount":109},[],{"trials":5193,"activeCount":109},[],{"trials":5195,"activeCount":109},[5196],{"nctId":5197,"briefTitle":5198,"status":102,"phases":5199,"primaryCompletion":5200,"completion":5201,"start":5202,"enrollment":5203,"conditions":5204,"interventions":5206},"NCT03789968","The Incidence and Severity of Drug Interactions Before and After Switching Antiretroviral Therapy to Bictegravir\u002FEmtricitabine\u002FTenofovir Alafenamide in Treatment Experienced Patients",[],"2020-09-05","2020-10-05","2019-09-01",411,[5205],"HIV\u002FAIDS",[5182],{"intervention":5208,"totalTrials":132,"cells":5209},"Depacon IV and Depakote ER",{"EARLY_PHASE1":5210,"PHASE1":5212,"PHASE2":5214,"PHASE3":5216,"PHASE4":5218,"NA":5220},{"trials":5211,"activeCount":109},[],{"trials":5213,"activeCount":109},[],{"trials":5215,"activeCount":109},[],{"trials":5217,"activeCount":109},[],{"trials":5219,"activeCount":109},[],{"trials":5221,"activeCount":109},[5222],{"nctId":5223,"briefTitle":5224,"status":102,"phases":5225,"primaryCompletion":3519,"completion":5226,"start":5227,"enrollment":1230,"conditions":5228,"interventions":5229},"NCT00203242","An Open Label Study Using Consecutive Intravenous Depacon With Oral Depakote ER for the Treatment of Cluster Headaches.",[91],"2006-12","2003-07",[2119],[5208],{"intervention":5231,"totalTrials":132,"cells":5232},"lamotrigine",{"EARLY_PHASE1":5233,"PHASE1":5235,"PHASE2":5237,"PHASE3":5239,"PHASE4":5241,"NA":5243},{"trials":5234,"activeCount":109},[],{"trials":5236,"activeCount":109},[],{"trials":5238,"activeCount":109},[],{"trials":5240,"activeCount":109},[],{"trials":5242,"activeCount":109},[],{"trials":5244,"activeCount":109},[5245],{"nctId":5246,"briefTitle":5247,"status":102,"phases":5248,"primaryCompletion":4447,"completion":3495,"start":5249,"enrollment":1480,"conditions":5250,"interventions":5251},"NCT00203229","Research Study to Test Safety and Effectiveness of Investigational Drug in Patients With Trigeminal Neuralgia",[91],"2003-06",[3138],[5231]]